US20030072718A1 - Methods and compositions for the dry powder formulation of interferons - Google Patents
Methods and compositions for the dry powder formulation of interferons Download PDFInfo
- Publication number
- US20030072718A1 US20030072718A1 US10/245,704 US24570402A US2003072718A1 US 20030072718 A1 US20030072718 A1 US 20030072718A1 US 24570402 A US24570402 A US 24570402A US 2003072718 A1 US2003072718 A1 US 2003072718A1
- Authority
- US
- United States
- Prior art keywords
- composition
- interferon
- dry powder
- spray
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates generally to methods and compositions for the dry powder formulation of cytokines, especially interferons. More particularly, the present invention relates to the spray drying of interferons (IFNs) to produce dry powder formulations of high potency.
- IFNs interferons
- Interferons are cytokines useful in the treatment of a variety of human diseases ranging from cancer to immune system enhancement. Interferons are commonly formulated as isotonic aqueous solutions for parenteral administration. Recently, clinicians have sought alternative routes of administration for interferons more suitable to long term use by patients. Particularly, aerosol formulations of interferons have been produced for pulmonary delivery as described in WO 91/16038. The formulation is dispersed by volatilization of a liquid propellent. The patent teaches adding a surfactant or the like to improve the dispersibility of a human interferon from a freon delivery system.
- An object of the present invention is to provide an interferon-containing composition suitable for long-term pulmonary administration to a patient in need thereof.
- Another object of this invention is to provide an interferon-containing powdered composition that is administered by inhalation in a manner that is free of a liquid propellant such as a FREON or carbon dioxide.
- Another object of this invention is to provide an interferon-containing powdered composition that can be easily manufactured by a method that maintains a high percentage of interferon activity.
- Still another object of this invention is to provide an interferon-containing composition that exhibits a high level of stability of the interferon over time.
- One aspect of this invention is an interferon-based dry powder composition for pulmonary delivery, said composition comprising a therapeutically effective amount of interferon in combination with a pharmaceutically acceptable carrier.
- Another aspect of this invention is a unit dosage form for pulmonary delivery of interferon, which dosage form comprises a unit receptacle containing the interferon-based dry powder composition of this invention.
- a third aspect of this invention is a method of treating a disease state responsive to treatment by interferon, which method comprises administering a physiologically effective amount of the interferon-based dry powder composition to the pulmonary region of the lung or a subject in need thereof.
- Still another aspect of this invention is a method for aerosolizing the interferon-based dry powder composition that comprise dispersing an amount of the dry powder composition in a gas stream to form an aerosol and capturing the aerosol in a chamber having a mouthpiece for subsequent inhalation by a patient.
- Still another aspect of this invention is a method for preparing the interferon-based dry powder composition that comprises spray-drying an aqueous mixture of the interferon and the carrier under conditions to provide a respirable dry powder.
- the present invention is based at least in part on the higher potency and improved flow characteristics of interferon-based dry powder compositions produced by spray drying according to the present invention.
- Higher potency means that the resulting interferon-based composition has a higher percentage of physiologically active interferon than compositions prepared by other methods.
- the compositions of the invention are readily aerosolized and rapidly absorbed through the lungs of a host when delivered by a dry powder inhaler.
- interferon is meant to include the family of naturally-occurring or recombinantly prepared small proteins and glycoproteins (sometimes referred to as cytokines) with molecular weight between approximately 15,000 and 27,000 daltons and having interferon-like activity. Generally, such activity is exerted by binding to specific membrane receptors on a cell surface. Once bound, interferons initiate a complex series of intracellular events that vary among the various interferons. Interferons are useful in the treatment of a variety of human conditions varying from cancer to immune system suppression. Naturally occurring interferons are produced and secreted by cells in response to viral infections and to synthetic and biological inducers.
- interferons are modified versions of the naturally occurring material and are prepared using recombinant DNA technology. Interferon is sometimes abbreviated as “IFN” and shall be so abbreviated in this application. Examples of interferons include, e.g.
- IFN-alpha-2A recombinant Roferon® A-Roche Laboratories
- IFN-alpha-2B recombinant Intron® A-Shering
- IFN-alpha-N3 human leukocyte derived Alferon® N-Purdue Frederick
- IFN-gamma-1B Actimmune®-Genentech
- IFN-beta recombinant Betaseron®-Chiron, Berlex
- IFN-beta naturally occurring Feron®-Toray, Japan
- U.S. Pat. No. 4,503,035 issued Mar. 5, 1985 to Pestka and Rubinstein gives examples of human leukocyte IFNs.
- IFN-beta is preferred, particularly naturally occurring IFN-beta.
- the term “powder” means a composition that consists of finely dispersed solid particles that are free flowing and capable of being readily dispersed in an inhalation device and subsequently inhaled by a subject so that the particles reach the lungs to permit penetration into the alveoli.
- the powder is said to be “respirable.”
- the average particle size is less than about 10 microns ( ⁇ m) in diameter with a relatively uniform spheroidal shape distribution. More preferably the diameter is less than about 7.5 ⁇ m and most preferably less than about 5.0 ⁇ m.
- the particle size distribution is between about 0.1 ⁇ m and about 5 ⁇ m in diameter, particularly about 2 ⁇ m to about 5 ⁇ m.
- dry means that the composition has a moisture content such that the particles are readily dispersable in an inhalation device to form an aerosol.
- This moisture content is generally below about 10% by weight (%w) water, usually below about 5% w ard preferably less than about 3% w.
- terapéuticaally effective amount is the amount present in the composition that is needed to provide the desired level of interferon in the subject to be treated to give the anticipated physiological response. This amount is determined for each interferon on a case-by-case basis. Guidelines are given hereafter.
- physiologically effective amount is that amount delivered to a subject to give the desired palliative or curative effect. This amount is specific for each interferon and its ultimate approved dosage level. Guidelines are given hereafter.
- pharmaceutically acceptable carrier means that the carrier can be taken into the lungs with no significant adverse toxicological effects on the lungs.
- One aspect of this invention is an interferon-based dry powder composition for pulmonary delivery, the composition comprising a therapeutically effective amount of interferon in combination with a pharmaceutically acceptable carrier.
- the compositions of this invention have a higher IFN potency and greater dispersibility than other interferon compositions known in the art.
- IFN In the dry state IFN is an amorphous form.
- the IFNs suitable for use in the composition of this invention include the various IFN alphas, IFN betas and IFN gammas encompassed by the broad definition of IFN.
- the IFN alphas and IFN betas are preferred, with IFN beta being particularly preferred.
- the composition is particularly valuable for naturally occurring IFN beta, for example that available through Toray Industries, Inc. in Japan.
- a therapeutically effective amount of IFN will vary in the composition depending on the biological activity of the IFN employed and the amount needed in a unit dosage form. Because IFN is so highly active it must be manufactured in a unit basis in a manner that allows for ready manipulation by the formulator and by the consumer. This generally means that a unit dosage will be between about 0.5 mg and 15 mg of total material in the dry powder composition, preferably between about 2 mg and 10 mg. Generally, the amount of IFN in the composition will vary from about 0.05%w to about 5.0% w. Most preferably the composition will be about 0.2% to about 2.0% w IFN.
- the amount of the pharmaceutically acceptable carrier is that amount needed to provide the necessary stability, dispersibility, consistency and bulking characteristics to ensure a uniform pulmonary delivery of the composition to a subject in need thereof. Numerically the amount may be from about 95.0% w to about 99.95% w, depending on the activity of the IFN being employed. Preferably about 98% w to about 99.8% w will be used.
- the carrier may be one or a combination of two or more pharmaceutical excipients, but will generally be substantially free of any “penetration enhancers.”
- “Penetration enhancers” are surface active compounds which promote penetration of a drug through a mucosal membrane or lining and are proposed for use in intranasal, intrarectal, and intravaginal drug formulations.
- Exemplary penetration enhancers include bile salts, e.g., taurocholate, glycocholate, and deoxycholate; fusidates, e.g., taurodehydrofusidate; and biocompatible detergents, e.g., Tweens, Laureth-9, and the like.
- penetration enhancers in formulations for the lungs, however, is generally undesirable because of the epithelial blood barrier in the lung can be adversely affected by such surface active compounds.
- the dry powder compositions of the present invention are readily absorbed in the lungs without the need to employ penetration enhancers.
- the types of pharmaceutical excipients that are useful as carriers in this invention include stabilizers such as human serum albumin (HSA), bulking agents such as carbohydrates, amino acids and polypeptides; pH adjusters or buffers; salts such as sodium chloride; and the like. These carriers may be in a crystalline or amorphous form or may be a mixture of the two.
- HSA human serum albumin
- bulking agents such as carbohydrates, amino acids and polypeptides
- pH adjusters or buffers such as sodium chloride
- salts such as sodium chloride
- HSA is particularly valuable as a carrier in that it provides excellent stabilization of IFN in solution.
- Bulking agents that are particularly valuable include compatible carbohydrates, polypeptides, amino acids or combinations thereof.
- Suitable carbohydrates include monosaccharides such as galactose, D-mannose, sorbose, and the like; disaccharides, such as lactose, trehalose, and the like; cyclodextrins, such as 2-hydroxypropyl- ⁇ -cyclodextrin; and polysaccharides, such as raffinose, maltodextrins, dextrans, and the like; alditols, such as mannitol, xylitol, and the like.
- a preferred group of carbohydrates includes lactose, threhalose, raffinose maltodextrins, and mannitol.
- Suitable polypeptides include aspartame.
- Amino acids include alanine and glycine, with glycine being preferred.
- Additives which are minor components of the composition of this invention, may be included for conformational stability during spray drying and for improving dispersibility of the powder.
- additives include hydrophobic amino acids such tryptophan, tyrosine, lucine, phenylalanine, and the like.
- Suitable pH adjusters or buffers include organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, and the like; sodium citrate is preferred.
- Another aspect of this invention is a unit dosage form for pulmonary delivery of interferon, which dosage form comprises a unit dosage receptacle containing an interferon-based dry powder composition, which composition comprises a therapeutically effective amount of an interferon in combination with a pharmaceutically acceptable carrier.
- the composition of this invention (as discussed hereinbefore) is placed within a suitable dosage receptacle in an amount sufficient to provide a subject with IFN for a unit dosage treatment.
- the dosage receptacle is one that fits within a suitable inhalation device to allow for the aerosolization of the interferon-based dry powder composition by dispersion into a gas stream to form an aerosol and then capturing the aerosol so produced in a chamber having a mouthpiece attached for subsequent inhalation by a subject in need of treatment.
- Such a dosage receptacle includes any container enclosing the composition known in the art such as gelatin or plastic capsules with a removable portion that allows a stream of gas (e.g., air) to be directed into the container to disperse the dry powder composition.
- a stream of gas e.g., air
- Such containers are exemplified by those shown in U.S. Pat. Nos. 4,227,522 issued Oct. 14, 1980; U.S. Pat. No. 4,192,309 issued Mar. 11, 1980; and U.S. Pat. No. 4,105,027 issued Aug. 8, 1978.
- Suitable containers also include those used in conjunction with Glaxo's Ventolin Rotohaler brand powder inhaler or Fison's Spinhaler brand powder inhaler.
- Another suitable unit-dose container which provides a superior moisture barrier is formed from an aluminum foil plastic laminate.
- the IFN-beta powder is filled by weight or by volume into the depression in the formable foil and hermetically sealed with a covering foil-plastic laminate.
- Such a container for use with a powder inhalation device is described in U.S. Pat. No. 4,778,054 and is used with Glaxo's Diskhaler® (U.S. Pat. Nos. 4,627,432; 4,811,731; and 5,035,237). All of these references are incorporated herein by reference.
- Another aspect of this invention is a method of treating a condition responsive to treatment by interferon, which method comprises pulmonarily administering to a subject in need thereof a physiologically effective amount of an interferon-based dry powder composition that comprises a therapeutically effective amount of an interferon in combination with a pharmaceutically acceptable carrier.
- Conditions that may be treated by the composition of this invention include those conditions that are responsive generally to treatment with IFN.
- IFN alpha is used to treat hepatitis B and C, Hairy Cell Leukemia, chronic hepatitis Non A, Non B/C and Kaposi's Sarcoma
- IFN beta is used to treat multiple sclerosis, brain tumor, skin cancer and hepatitis B and C
- IFN gamma is used to treat chronic granulomatous disease.
- the physiologically effective amount needed to treat a particular condition or disease state will depend on the individual, the condition, length of treatment, the regularity of treatment, the type of IFN, and other factors, but can be determined by one of ordinary skill in the medicinal arts.
- the dosage may range from 0.25 ⁇ 10 6 IU to 50 ⁇ 10 6 IU per person per day depending on the prescribing doctor's diagnosis.
- an induction dosage of IFN alpha recombinant (Roferon®A-Roche Laboratories) for treatment of hairy cell leukemia may be 3 ⁇ 10 6 IU daily for 16-24 weeks with a maintenance dose of 3 ⁇ 10 6 IU three times per week.
- Other dosage regimes may be determined through clinical trials and reference to the Physicians Desk Reference® for 1994 as supplemented.
- the effective absorption by a host of dry powder interferon according to the present invention results from a rapid dissolution in the ultra-thin ( ⁇ 0.1 fm) fluid layer of the alveolar lining of the lung.
- the particles of the present invention thus have a mean size which is from 10 to 50 times larger than the lung fluid layer, making it unexpected that the particles are dissolved and the interferon systemically absorbed in a rapid manner for either local lung or systemic treatment.
- the aerosolized interferon-based dry powders of this invention are particularly useful in place of parenteral delivery.
- the methods and compositions of the present invention will be particularly valuable in chronic treatment protocols where a patient can self-medicate.
- the patient can achieve a desired dosage by inhaling an appropriate amount of interferon, as just described.
- the efficiency of systemic interferon delivery via the method as just described will typically be in the range from about 15% to 50%, with individual dosages (on a per inhalation basis), typically being in the range from about 3 million IU to about 50 million IU during a single respiratory administration.
- the desired dosage may be effected by the patient taking from 1 breath to 5 breaths.
- Still another aspect of this invention is a method for aerosolizing an interferon-based dry powder composition that comprises a therapeutically effective amount of an interferon in combination with a pharmaceutically acceptable carrier, which method comprises dispersing an amount of the dry powder composition in a gas stream to form an aerosol and capturing the aerosol in a chamber having a mouthpiece for subsequent inhalation by patient.
- Still another aspect of this invention is a method for preparing an interferon-based dry powder composition of this invention that comprises spray-drying an aqueous mixture of the interferon and a pharmaceutically acceptable carrier having an interferon-stabilizing pH under conditions to provide a respirable dry powder composition.
- Spray drying is a process in which a homogeneous aqueous mixture of IFN and the carrier is introduced via a nozzle (e.g., a two fluid nozzle), spinning disc or an equivalent device into a hot gas stream to atomize the solution to form fine droplets.
- the aqueous mixture may be a solution, suspension, slurry, or the like, but needs to be homogeneous to ensure uniform distribution of the components in the mixture and ultimately the powdered composition.
- the aqueous mixture is a solution.
- the solvent generally water, rapidly evaporates from the droplets producing a fine dry powder having particles 1 to 5 ⁇ m in diameter.
- the protein is not degraded when it is exposed to the hot drying gas, and the interferon powders can be prepared having sufficient purity for pharmaceutical use.
- An acceptable purity is defined as less than 5% degradation products and contaminates, preferably less than 3% and most preferably less than 1%.
- the spray drying is done under conditions that result in substantially amorphous powder of homogeneous constitution having a particle size that is respirable, a low moisture content and flow characteristics that allow for ready aerosoiization.
- the particle size of the resulting powder is such that more than about 98% of the mass is in particles having a diameter of about 10 ⁇ m or less with about 90% of the mass being in particles having a diameter less than 5 ⁇ m.
- about 95% (preferably more than 95%) of the mass will have particles with a diameter of less than 10 ⁇ m with about 80% (preferably more than 80%) of the mass of the particles having a diameter of less than 5 ⁇ m.
- interferon dry powders of higher potency and improved flow characteristics are prepared by spray drying, where, bulk interferon, preferably IFN-beta but suitably other forms of interferon, is prepared in solution to have a concentration from 0.0005% by weight to 0.02% by weight, usually from 0.001% to 0.005%.
- the solutions may contain a stabilizer to maintain the chemical stability of the IFN-beta in solution such as HSA in a concentration from 0.01% to 1.0% by weight and preferably 0.05% to 0.25% by weight and may contain other material such as a salt or preservative that is present as a result of the preparation of bulk IFN.
- the solutions may then be sprayed dried in conventional spray drying equipment from commercial suppliers, such as Buchi, Niro, Yamato Chemical Co., Okawara Kakoki Co., and the like, resulting in a substantially amorphous particulate product.
- spraying methods as rotary atomization, pressure atomization and two-fluid atomization can be used.
- the devices used in these processes include “Pulvis Mini-Spray GA-32” and “Pulvis Spray Drier DL-41”, manufactured by Yamato Chemical Co., or “Spray Drier CL-8,” “Spray Drier L-8,” “Spray Drier FL-12,” “Spray Drier FL-16” or “Spray Drier FL-20,” manufactured by Okawara Kakoki Co., can be used for the method of spraying using rotary-disk atomizer.
- nozzle types “1A,” “1,” “2A,” “2,” “3” and the like, manufactured by Yamato Chemical Co. can be used for the above-mentioned spray-drier, manufactured by the same company.
- disks type “MC-50,” “MC-65” or “MC-85,” manufactured by Okawara Kakoki Co. can be used as rotary disks of the spray-drier atomizer, manufactured by the same company.
- the temperature of the inlet of the gas used to dry the sprayed materials such that it does not cause heat deactivation of the sprayed material.
- the range of temperatures may vary between about 50° C. to about 200° C., preferable between about 50° C. and 100° C.
- the temperature of the outlet gas used to dry the sprayed material may vary between about 0° C. and about 150°, preferably between 0° C. and 90° C., and even more preferably between 0° C. and 60° C.
- inlet and outlet temperatures above about 55° C. can be used is surprising in view of the fact that IFN starts deactivating at that temperature, with nearly complete deactivation occurring at about 70° C.
- high potency IFN powder can be prepared such that the number of inhalations required to deliver even high dosages of IFN can be substantially reduced, often to only a single inhalation.
- Interferon dry powders suitable for use in the present invention are substantially amorphous, essentially lacking any crystalline structure. Dry powder interferons are prepared by spray drying under conditions which result in a substantially amorphous powder having a particle size within the above-stated range.
- bulk interferon preferably IFN- ⁇ but suitably other forms of interferon
- a physiologically-acceptable aqueous solution typically containing sodium chloride, optionally with a buffer, having a pH in the range from about 2 to 9.
- the interferon is dissolved at a concentration from 0.01% by weight to 1% by weight, usually from 0.1% to 0.2%.
- the solutions may then be spray dried in conventional spray drying equipment from commercial suppliers, such as Buchi, Niro Yamato, Okawara Kakoki and the like, resulting in a substantially amorphous particulate product.
- the interferon dry powders of the present invention may optionally be combined with pharmaceutical carriers or excipients which are suitable for respiratory and pulmonary administration.
- Such carriers may serve simply as bulking agents when it is desired to reduce the interferon concentration in the powder which is being delivered to a patient, but may also serve to enhance the stability of the interferon compositions and to improve the dispersibility of the powder within a powder dispersion device in order to provide more efficient and reproducible delivery of the interferon and to improve handling characteristics of the interferon such as flowability and consistency to facilitate manufacturing and powder filling.
- Such carrier materials may be combined with the interferon prior to spray drying, i.e., by adding the carrier material to the purified bulk solution. In that way, the carrier particles will be formed simultaneously with the IFN particles to produce a homogeneous powder.
- the carriers may be separately prepared in a dry powder form and combined with the dry powder interferon by blending.
- the powder carriers will usually be crystalline (to avoid water absorption), but might in some cases be amorphous or mixtures of crystalline and amorphous.
- the size of the carrier particles may be selected to improve the flowability of the IFN powder, typically being in the range from 25 ⁇ m to 100 ⁇ m.
- a preferred carrier material is crystalline lactose having a size in the above-stated range.
- This example sets forth a method of preparing a composition of this invention.
- the resulting aqueous mixture is fed to a Buchi Laboratory Spray Dryer under the following conditions to give a composition of this invention: Temperature of the aqueous mixture 4° C.-10° C. Inlet temperature 115° C.-125° C. Feed rate 6 mL/min Outlet temperature 60° C.-70° C.
- the outlet temperature is maintained at about 70° C. for about 15 minutes by slowly decreasing the inlet temperature.
- This provides a secondary drying to give an IFN-based dry powder composition having a water content of less than 3% as measured by a coulombic Karl Fischer method.
- the composition (% w based on total solids) is constituted as follows: 1.9% w IFN-beta 98.1% w Carrier (75.8% HSA, 22.3 NaCl)
- This example sets forth a method of preparing a composition of this invention wherein the carrier includes a bulking agent, i.e., mannitol.
- a bulking agent i.e., mannitol.
- Mannitol is dissolved in natural human IFN-beta described in Example i.
- the concentration of mannitol was 5.75 mg/mL.
- the resulting aqueous mixture is fed to a Buchi Laboratory Spray Dryer under the following conditions: Temperature of the aqueous mixture 4° C.-10° C. Inlet temperature 115° C.-125° C. Feed rate 5 mL/min Outlet temperature 60° C.-70° C. Secondary drying—15 minutes at 70° C.
- This example sets forth a method for preparing a composition of this invention wherein no bulking agent is present in the composition.
- the spray pressure was 1 kg/cm 2
- the flow capacity of the hot air was 0.40 to 0.42 m 3 /min
- the rate of solution transmission was 4.3 ml/min.
- the dry powder which was collected into a chamber using a cyclone, was recovered, and the interferon (IFN) activity was measured.
- the interferon activity was measured using an enzyme immunoassay (EIA) involving an anti-human interferon ⁇ antibody (S. Yamazaki et al., Immunoassay, 10, 57(1989)).
- the activity of the dry powder was measured by dissolving the dry powder using distilled water and comparing its interferon activity, corresponding to the light absorption at 280 nm, with the interferon activity prior to the spray-drying process. The results are shown in Table 1. The measurements were repeated three times, and the average values were used for the comparison. The error in the relative activity in the table is a standard error ( ⁇ SE). TABLE 1 Natural human interferon ⁇ activity before and after spray-drying Relative activity (IU/A 280 unit) Remaining activity (%) Before spray-drying 4.11 ⁇ 0.11 100 After spray-drying 3.14 ⁇ 0.04 74.8
- the natural human interferon ⁇ showed an interferon activity which was 74.8% of its activity prior to the spray-drying process, indicating that it can be spray-dried while maintaining its activity.
- the dry powder obtained by the process of this invention was subjected to platinum coating and the shape of its grains was examined using a field emission scan electron microscope (model S-8000, manufactured by Hitachi Co.). Approximately 90% of the grains examined were grains with relatively smooth and large dents and protrusions in the grain surface, and with a grain diameter of approximately 10 ⁇ m. In addition, the resulting powder exhibited a moisture content of 5.6 wt % using the Karl Fischer method (coulometric titration Moisturemeter CA-06, manufactured by Mitsubishi Kasei Co.).
- This example sets forth a method for preparing an IFN/HSA/mannitol composition.
- the natural human interferon ⁇ maintained 81.0% of its activity compared with its activity prior to the spray-drying process.
- these results are surprising because a similar aqueous solution of the same quantity of natural human interferon ⁇ , HSA and mannitol started to deactivate at approximately 55° C., with almost complete deactivation occurring at 70° C.
- Example V While the IFN-based powder from Example IV and V are dispersible, the powder obtained from Example V was more readily dispersed than the powder obtained in Example IV.
- the grain shape was examined by subjecting the powder to platinum coating and using a field emission scan electron microscope (model S-8000, manufactured by Hitachi Co.), the grains were found to have a size similar to those of Example IV but a shape more IS rounded compares with the powder particles obtained in Example IV.
- the distribution of the grain diameter of the powder vas measured by dispersing it in ethanol anhydride and using a granulation analyzer (Microtrac FRA, manufactured by Nikkiso Co.), it was found that approximately 90% of the grains were distributed within the range of 1.6 to 9.3 ⁇ m. The moisture content was 0.74% wt, as measured by the Karl Fischer method of Example IV.
Abstract
Description
- This is a continuation-in-part of co-pending U.S. Patent Application 08/246,034, filed May 18, 1994.
- 1. Field of the Invention
- The present invention relates generally to methods and compositions for the dry powder formulation of cytokines, especially interferons. More particularly, the present invention relates to the spray drying of interferons (IFNs) to produce dry powder formulations of high potency.
- 2. Description of the Background Art
- Interferons are cytokines useful in the treatment of a variety of human diseases ranging from cancer to immune system enhancement. Interferons are commonly formulated as isotonic aqueous solutions for parenteral administration. Recently, clinicians have sought alternative routes of administration for interferons more suitable to long term use by patients. Particularly, aerosol formulations of interferons have been produced for pulmonary delivery as described in WO 91/16038. The formulation is dispersed by volatilization of a liquid propellent. The patent teaches adding a surfactant or the like to improve the dispersibility of a human interferon from a freon delivery system.
- Methods and compositions for the preparation of solid polypeptide microparticles as a pharmaceutical aerosol formulation are disclosed in WO 91/16038 wherein IFN-beta was prepared in dry powder form by lyophilizing an aqueous solution of IFN and jet milling following lyophilization. The purification of proteins of molecular weight in excess of 12,000, including human IFN is disclosed in U.S. Pat. No. 4,503,035. Low pH pharmaceutical compositions of recombinant IFN-beta are disclosed in WO 89/05158.
- Because interferons are fairly expensive compounds, it is highly desirable to have formulations of high potency with improved flow characteristics that can be used with high efficiency in dry powder inhalers to produce reproducible doses for pulmonary delivery.
- An object of the present invention is to provide an interferon-containing composition suitable for long-term pulmonary administration to a patient in need thereof. Another object of this invention is to provide an interferon-containing powdered composition that is administered by inhalation in a manner that is free of a liquid propellant such as a FREON or carbon dioxide.
- Another object of this invention is to provide an interferon-containing powdered composition that can be easily manufactured by a method that maintains a high percentage of interferon activity.
- Still another object of this invention is to provide an interferon-containing composition that exhibits a high level of stability of the interferon over time.
- Other objects may be apparent to one of ordinary skill upon reviewing the following specification and claims.
- One aspect of this invention is an interferon-based dry powder composition for pulmonary delivery, said composition comprising a therapeutically effective amount of interferon in combination with a pharmaceutically acceptable carrier.
- Another aspect of this invention is a unit dosage form for pulmonary delivery of interferon, which dosage form comprises a unit receptacle containing the interferon-based dry powder composition of this invention.
- A third aspect of this invention is a method of treating a disease state responsive to treatment by interferon, which method comprises administering a physiologically effective amount of the interferon-based dry powder composition to the pulmonary region of the lung or a subject in need thereof.
- Still another aspect of this invention is a method for aerosolizing the interferon-based dry powder composition that comprise dispersing an amount of the dry powder composition in a gas stream to form an aerosol and capturing the aerosol in a chamber having a mouthpiece for subsequent inhalation by a patient.
- Still another aspect of this invention is a method for preparing the interferon-based dry powder composition that comprises spray-drying an aqueous mixture of the interferon and the carrier under conditions to provide a respirable dry powder.
- The present invention is based at least in part on the higher potency and improved flow characteristics of interferon-based dry powder compositions produced by spray drying according to the present invention. Higher potency means that the resulting interferon-based composition has a higher percentage of physiologically active interferon than compositions prepared by other methods. The compositions of the invention are readily aerosolized and rapidly absorbed through the lungs of a host when delivered by a dry powder inhaler.
- In interpreting the claims to the various aspects of this invention, there are several important definitions that should be considered.
- The term “interferon” is meant to include the family of naturally-occurring or recombinantly prepared small proteins and glycoproteins (sometimes referred to as cytokines) with molecular weight between approximately 15,000 and 27,000 daltons and having interferon-like activity. Generally, such activity is exerted by binding to specific membrane receptors on a cell surface. Once bound, interferons initiate a complex series of intracellular events that vary among the various interferons. Interferons are useful in the treatment of a variety of human conditions varying from cancer to immune system suppression. Naturally occurring interferons are produced and secreted by cells in response to viral infections and to synthetic and biological inducers. Some interferons are modified versions of the naturally occurring material and are prepared using recombinant DNA technology. Interferon is sometimes abbreviated as “IFN” and shall be so abbreviated in this application. Examples of interferons include, e.g. IFN-alpha-2A recombinant (Roferon® A-Roche Laboratories), IFN-alpha-2B recombinant (Intron® A-Shering), IFN-alpha-N3 human leukocyte derived (Alferon® N-Purdue Frederick), IFN-gamma-1B (Actimmune®-Genentech), IFN-beta recombinant (Betaseron®-Chiron, Berlex), IFN-beta naturally occurring (Feron®-Toray, Japan), and the like. U.S. Pat. No. 4,503,035 issued Mar. 5, 1985 to Pestka and Rubinstein gives examples of human leukocyte IFNs. For purposes of this invention IFN-beta is preferred, particularly naturally occurring IFN-beta.
- The term “powder” means a composition that consists of finely dispersed solid particles that are free flowing and capable of being readily dispersed in an inhalation device and subsequently inhaled by a subject so that the particles reach the lungs to permit penetration into the alveoli. Thus, the powder is said to be “respirable.” Preferably the average particle size is less than about 10 microns (μm) in diameter with a relatively uniform spheroidal shape distribution. More preferably the diameter is less than about 7.5 μm and most preferably less than about 5.0 μm. Usually the particle size distribution is between about 0.1 μm and about 5 μm in diameter, particularly about 2 μm to about 5 μm.
- The term “dry” means that the composition has a moisture content such that the particles are readily dispersable in an inhalation device to form an aerosol. This moisture content is generally below about 10% by weight (%w) water, usually below about 5% w ard preferably less than about 3% w.
- The term “therapeutically effective amount” is the amount present in the composition that is needed to provide the desired level of interferon in the subject to be treated to give the anticipated physiological response. This amount is determined for each interferon on a case-by-case basis. Guidelines are given hereafter.
- The term “physiologically effective amount” is that amount delivered to a subject to give the desired palliative or curative effect. This amount is specific for each interferon and its ultimate approved dosage level. Guidelines are given hereafter.
- The term “pharmaceutically acceptable” carrier means that the carrier can be taken into the lungs with no significant adverse toxicological effects on the lungs.
- One aspect of this invention is an interferon-based dry powder composition for pulmonary delivery, the composition comprising a therapeutically effective amount of interferon in combination with a pharmaceutically acceptable carrier.
- In general, the compositions of this invention have a higher IFN potency and greater dispersibility than other interferon compositions known in the art. In the dry state IFN is an amorphous form. The IFNs suitable for use in the composition of this invention include the various IFN alphas, IFN betas and IFN gammas encompassed by the broad definition of IFN. The IFN alphas and IFN betas are preferred, with IFN beta being particularly preferred. The composition is particularly valuable for naturally occurring IFN beta, for example that available through Toray Industries, Inc. in Japan.
- A therapeutically effective amount of IFN will vary in the composition depending on the biological activity of the IFN employed and the amount needed in a unit dosage form. Because IFN is so highly active it must be manufactured in a unit basis in a manner that allows for ready manipulation by the formulator and by the consumer. This generally means that a unit dosage will be between about 0.5 mg and 15 mg of total material in the dry powder composition, preferably between about 2 mg and 10 mg. Generally, the amount of IFN in the composition will vary from about 0.05%w to about 5.0% w. Most preferably the composition will be about 0.2% to about 2.0% w IFN.
- The amount of the pharmaceutically acceptable carrier is that amount needed to provide the necessary stability, dispersibility, consistency and bulking characteristics to ensure a uniform pulmonary delivery of the composition to a subject in need thereof. Numerically the amount may be from about 95.0% w to about 99.95% w, depending on the activity of the IFN being employed. Preferably about 98% w to about 99.8% w will be used.
- The carrier may be one or a combination of two or more pharmaceutical excipients, but will generally be substantially free of any “penetration enhancers.” “Penetration enhancers” are surface active compounds which promote penetration of a drug through a mucosal membrane or lining and are proposed for use in intranasal, intrarectal, and intravaginal drug formulations. Exemplary penetration enhancers include bile salts, e.g., taurocholate, glycocholate, and deoxycholate; fusidates, e.g., taurodehydrofusidate; and biocompatible detergents, e.g., Tweens, Laureth-9, and the like. The use of penetration enhancers in formulations for the lungs, however, is generally undesirable because of the epithelial blood barrier in the lung can be adversely affected by such surface active compounds. The dry powder compositions of the present invention are readily absorbed in the lungs without the need to employ penetration enhancers.
- The types of pharmaceutical excipients that are useful as carriers in this invention include stabilizers such as human serum albumin (HSA), bulking agents such as carbohydrates, amino acids and polypeptides; pH adjusters or buffers; salts such as sodium chloride; and the like. These carriers may be in a crystalline or amorphous form or may be a mixture of the two.
- It has been found that HSA is particularly valuable as a carrier in that it provides excellent stabilization of IFN in solution.
- Bulking agents that are particularly valuable include compatible carbohydrates, polypeptides, amino acids or combinations thereof. Suitable carbohydrates include monosaccharides such as galactose, D-mannose, sorbose, and the like; disaccharides, such as lactose, trehalose, and the like; cyclodextrins, such as 2-hydroxypropyl-β-cyclodextrin; and polysaccharides, such as raffinose, maltodextrins, dextrans, and the like; alditols, such as mannitol, xylitol, and the like. A preferred group of carbohydrates includes lactose, threhalose, raffinose maltodextrins, and mannitol. Suitable polypeptides include aspartame. Amino acids include alanine and glycine, with glycine being preferred.
- Additives, which are minor components of the composition of this invention, may be included for conformational stability during spray drying and for improving dispersibility of the powder. These additives include hydrophobic amino acids such tryptophan, tyrosine, lucine, phenylalanine, and the like.
- Suitable pH adjusters or buffers include organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, and the like; sodium citrate is preferred.
- The unit dosage form, method of treatment, and process of preparation of this invention are described hereafter.
- Unit Dosage Form
- Another aspect of this invention is a unit dosage form for pulmonary delivery of interferon, which dosage form comprises a unit dosage receptacle containing an interferon-based dry powder composition, which composition comprises a therapeutically effective amount of an interferon in combination with a pharmaceutically acceptable carrier.
- In this aspect of the invention, the composition of this invention (as discussed hereinbefore) is placed within a suitable dosage receptacle in an amount sufficient to provide a subject with IFN for a unit dosage treatment. The dosage receptacle is one that fits within a suitable inhalation device to allow for the aerosolization of the interferon-based dry powder composition by dispersion into a gas stream to form an aerosol and then capturing the aerosol so produced in a chamber having a mouthpiece attached for subsequent inhalation by a subject in need of treatment. Such a dosage receptacle includes any container enclosing the composition known in the art such as gelatin or plastic capsules with a removable portion that allows a stream of gas (e.g., air) to be directed into the container to disperse the dry powder composition. Such containers are exemplified by those shown in U.S. Pat. Nos. 4,227,522 issued Oct. 14, 1980; U.S. Pat. No. 4,192,309 issued Mar. 11, 1980; and U.S. Pat. No. 4,105,027 issued Aug. 8, 1978. Suitable containers also include those used in conjunction with Glaxo's Ventolin Rotohaler brand powder inhaler or Fison's Spinhaler brand powder inhaler. Another suitable unit-dose container which provides a superior moisture barrier is formed from an aluminum foil plastic laminate. The IFN-beta powder is filled by weight or by volume into the depression in the formable foil and hermetically sealed with a covering foil-plastic laminate. Such a container for use with a powder inhalation device is described in U.S. Pat. No. 4,778,054 and is used with Glaxo's Diskhaler® (U.S. Pat. Nos. 4,627,432; 4,811,731; and 5,035,237). All of these references are incorporated herein by reference.
- Method of Treating a Disease State
- Another aspect of this invention is a method of treating a condition responsive to treatment by interferon, which method comprises pulmonarily administering to a subject in need thereof a physiologically effective amount of an interferon-based dry powder composition that comprises a therapeutically effective amount of an interferon in combination with a pharmaceutically acceptable carrier.
- Conditions that may be treated by the composition of this invention include those conditions that are responsive generally to treatment with IFN. For example, IFN alpha is used to treat hepatitis B and C, Hairy Cell Leukemia, chronic hepatitis Non A, Non B/C and Kaposi's Sarcoma; IFN beta is used to treat multiple sclerosis, brain tumor, skin cancer and hepatitis B and C; and IFN gamma is used to treat chronic granulomatous disease.
- The physiologically effective amount needed to treat a particular condition or disease state will depend on the individual, the condition, length of treatment, the regularity of treatment, the type of IFN, and other factors, but can be determined by one of ordinary skill in the medicinal arts. The dosage may range from 0.25×106 IU to 50×106 IU per person per day depending on the prescribing doctor's diagnosis. For example an induction dosage of IFN alpha recombinant (Roferon®A-Roche Laboratories) for treatment of hairy cell leukemia may be 3×106 IU daily for 16-24 weeks with a maintenance dose of 3×106 IU three times per week. Other dosage regimes may be determined through clinical trials and reference to the Physicians Desk Reference® for 1994 as supplemented.
- It is presently believed that the effective absorption by a host of dry powder interferon according to the present invention results from a rapid dissolution in the ultra-thin (<0.1 fm) fluid layer of the alveolar lining of the lung. The particles of the present invention thus have a mean size which is from 10 to 50 times larger than the lung fluid layer, making it unexpected that the particles are dissolved and the interferon systemically absorbed in a rapid manner for either local lung or systemic treatment. An understanding of the precise mechanism, however, is not necessary for practicing the present invention as described herein.
- The aerosolized interferon-based dry powders of this invention are particularly useful in place of parenteral delivery. Thus, the methods and compositions of the present invention will be particularly valuable in chronic treatment protocols where a patient can self-medicate. The patient can achieve a desired dosage by inhaling an appropriate amount of interferon, as just described. The efficiency of systemic interferon delivery via the method as just described will typically be in the range from about 15% to 50%, with individual dosages (on a per inhalation basis), typically being in the range from about 3 million IU to about 50 million IU during a single respiratory administration. Thus, the desired dosage may be effected by the patient taking from 1 breath to 5 breaths.
- Method for Aerosolizing the Powder
- Still another aspect of this invention is a method for aerosolizing an interferon-based dry powder composition that comprises a therapeutically effective amount of an interferon in combination with a pharmaceutically acceptable carrier, which method comprises dispersing an amount of the dry powder composition in a gas stream to form an aerosol and capturing the aerosol in a chamber having a mouthpiece for subsequent inhalation by patient.
- A further detailed description of this method is found in pending U.S. patent applications Ser. Nos. 07/910,048 and 08/207,472, both of which are incorporated herein by reference.
- Preparing the Compositions
- Still another aspect of this invention is a method for preparing an interferon-based dry powder composition of this invention that comprises spray-drying an aqueous mixture of the interferon and a pharmaceutically acceptable carrier having an interferon-stabilizing pH under conditions to provide a respirable dry powder composition.
- Spray drying is a process in which a homogeneous aqueous mixture of IFN and the carrier is introduced via a nozzle (e.g., a two fluid nozzle), spinning disc or an equivalent device into a hot gas stream to atomize the solution to form fine droplets. The aqueous mixture may be a solution, suspension, slurry, or the like, but needs to be homogeneous to ensure uniform distribution of the components in the mixture and ultimately the powdered composition. Preferably the aqueous mixture is a solution. The solvent, generally water, rapidly evaporates from the droplets producing a fine dry powder having particles 1 to 5 μm in diameter. Surprisingly, the protein is not degraded when it is exposed to the hot drying gas, and the interferon powders can be prepared having sufficient purity for pharmaceutical use. An acceptable purity is defined as less than 5% degradation products and contaminates, preferably less than 3% and most preferably less than 1%.
- The spray drying is done under conditions that result in substantially amorphous powder of homogeneous constitution having a particle size that is respirable, a low moisture content and flow characteristics that allow for ready aerosoiization. Preferably the particle size of the resulting powder is such that more than about 98% of the mass is in particles having a diameter of about 10 μm or less with about 90% of the mass being in particles having a diameter less than 5 μm. Alternatively, about 95% (preferably more than 95%) of the mass will have particles with a diameter of less than 10 μm with about 80% (preferably more than 80%) of the mass of the particles having a diameter of less than 5 μm.
- According to the methods of the present invention, interferon dry powders of higher potency and improved flow characteristics are prepared by spray drying, where, bulk interferon, preferably IFN-beta but suitably other forms of interferon, is prepared in solution to have a concentration from 0.0005% by weight to 0.02% by weight, usually from 0.001% to 0.005%. The solutions may contain a stabilizer to maintain the chemical stability of the IFN-beta in solution such as HSA in a concentration from 0.01% to 1.0% by weight and preferably 0.05% to 0.25% by weight and may contain other material such as a salt or preservative that is present as a result of the preparation of bulk IFN. The solutions may then be sprayed dried in conventional spray drying equipment from commercial suppliers, such as Buchi, Niro, Yamato Chemical Co., Okawara Kakoki Co., and the like, resulting in a substantially amorphous particulate product.
- For the spraying process, such spraying methods as rotary atomization, pressure atomization and two-fluid atomization can be used. Examples of the devices used in these processes include “Pulvis Mini-Spray GA-32” and “Pulvis Spray Drier DL-41”, manufactured by Yamato Chemical Co., or “Spray Drier CL-8,” “Spray Drier L-8,” “Spray Drier FL-12,” “Spray Drier FL-16” or “Spray Drier FL-20,” manufactured by Okawara Kakoki Co., can be used for the method of spraying using rotary-disk atomizer.
- While no special restrictions are placed on the nozzle of the atomizer used in the process of spraying, it is recommended to use a nozzle which can produce a spray-dry composition with a grain diameter suitable for nasal, pharyngeal or pulmonary administration. For example, nozzle types “1A,” “1,” “2A,” “2,” “3” and the like, manufactured by Yamato Chemical Co., can be used for the above-mentioned spray-drier, manufactured by the same company. In addition, disks type “MC-50,” “MC-65” or “MC-85,” manufactured by Okawara Kakoki Co., can be used as rotary disks of the spray-drier atomizer, manufactured by the same company.
- While no particular restrictions are placed on the gas used to dry the sprayed material, it is recommended to use air, nitrogen gas or an inert gas. The temperature of the inlet of the gas used to dry the sprayed materials such that it does not cause heat deactivation of the sprayed material. The range of temperatures may vary between about 50° C. to about 200° C., preferable between about 50° C. and 100° C. The temperature of the outlet gas used to dry the sprayed material, may vary between about 0° C. and about 150°, preferably between 0° C. and 90° C., and even more preferably between 0° C. and 60° C. The fact that inlet and outlet temperatures above about 55° C. can be used is surprising in view of the fact that IFN starts deactivating at that temperature, with nearly complete deactivation occurring at about 70° C.
- By minimizing the amount of stabilizer in the solution, high potency IFN powder can be prepared such that the number of inhalations required to deliver even high dosages of IFN can be substantially reduced, often to only a single inhalation.
- Interferon dry powders suitable for use in the present invention are substantially amorphous, essentially lacking any crystalline structure. Dry powder interferons are prepared by spray drying under conditions which result in a substantially amorphous powder having a particle size within the above-stated range. According to the method of the present invention, bulk interferon, preferably IFN-β but suitably other forms of interferon, is first dissolved in a physiologically-acceptable aqueous solution typically containing sodium chloride, optionally with a buffer, having a pH in the range from about 2 to 9. The interferon is dissolved at a concentration from 0.01% by weight to 1% by weight, usually from 0.1% to 0.2%. The solutions may then be spray dried in conventional spray drying equipment from commercial suppliers, such as Buchi, Niro Yamato, Okawara Kakoki and the like, resulting in a substantially amorphous particulate product.
- The interferon dry powders of the present invention may optionally be combined with pharmaceutical carriers or excipients which are suitable for respiratory and pulmonary administration. Such carriers may serve simply as bulking agents when it is desired to reduce the interferon concentration in the powder which is being delivered to a patient, but may also serve to enhance the stability of the interferon compositions and to improve the dispersibility of the powder within a powder dispersion device in order to provide more efficient and reproducible delivery of the interferon and to improve handling characteristics of the interferon such as flowability and consistency to facilitate manufacturing and powder filling.
- Such carrier materials may be combined with the interferon prior to spray drying, i.e., by adding the carrier material to the purified bulk solution. In that way, the carrier particles will be formed simultaneously with the IFN particles to produce a homogeneous powder. Alternatively, the carriers may be separately prepared in a dry powder form and combined with the dry powder interferon by blending. The powder carriers will usually be crystalline (to avoid water absorption), but might in some cases be amorphous or mixtures of crystalline and amorphous. The size of the carrier particles may be selected to improve the flowability of the IFN powder, typically being in the range from 25 μm to 100 μm. A preferred carrier material is crystalline lactose having a size in the above-stated range.
- Example I
- This example sets forth a method of preparing a composition of this invention.
- Approximately 50 mL of 10 mM sodium chloride solution of natural human IFN-beta comprising approximately 2 mg/ml HSA was prepared.
- The resulting aqueous mixture is fed to a Buchi Laboratory Spray Dryer under the following conditions to give a composition of this invention:
Temperature of the aqueous mixture 4° C.-10° C. Inlet temperature 115° C.-125° C. Feed rate 6 mL/min Outlet temperature 60° C.-70° C. - Once the aqueous mixture is consumed, the outlet temperature is maintained at about 70° C. for about 15 minutes by slowly decreasing the inlet temperature. This provides a secondary drying to give an IFN-based dry powder composition having a water content of less than 3% as measured by a coulombic Karl Fischer method. In this case the composition (% w based on total solids) is constituted as follows:
1.9% w IFN-beta 98.1% w Carrier (75.8% HSA, 22.3 NaCl) - By following the procedure of Example I, but increasing the outlet temperature to 75° C.-80° C. during the secondary drying stage, one obtains a composition of this invention having less than 1% w water.
- This example sets forth a method of preparing a composition of this invention wherein the carrier includes a bulking agent, i.e., mannitol.
- Mannitol is dissolved in natural human IFN-beta described in Example i. The concentration of mannitol was 5.75 mg/mL.
- The resulting aqueous mixture is fed to a Buchi Laboratory Spray Dryer under the following conditions:
Temperature of the aqueous mixture 4° C.-10° C. Inlet temperature 115° C.-125° C. Feed rate 5 mL/min Outlet temperature 60° C.-70° C. Secondary drying—15 minutes at 70° C. - Although the foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.
- This example sets forth a method for preparing a composition of this invention wherein no bulking agent is present in the composition.
- Approximately 100 ml of 10 mM sodium chloride solution of natural human interferon (obtained by culturing human normal diploid fibroblasts) (approximately 7×104 IU/ml) comprising approximately 2 mg/ml human serum albumin (HSA) were prepared, and spray-dried using the commercial spray-drier “Pulvis Mini-Spray GA-32,” manufactured by Yamato Chemical Co. The spray nozzle used was a 1A nozzle (φ0.4 mm) and the inlet temperature and the outlet temperature of the drying gas were 100° C. and 60° C., respectively. In addition, the spray pressure was 1 kg/cm2, the flow capacity of the hot air was 0.40 to 0.42 m3/min and the rate of solution transmission was 4.3 ml/min. After approximately 20 min. of spray-drying, the dry powder, which was collected into a chamber using a cyclone, was recovered, and the interferon (IFN) activity was measured. The interferon activity was measured using an enzyme immunoassay (EIA) involving an anti-human interferon β antibody (S. Yamazaki et al., Immunoassay, 10, 57(1989)). The activity of the dry powder was measured by dissolving the dry powder using distilled water and comparing its interferon activity, corresponding to the light absorption at 280 nm, with the interferon activity prior to the spray-drying process. The results are shown in Table 1. The measurements were repeated three times, and the average values were used for the comparison. The error in the relative activity in the table is a standard error (±SE).
TABLE 1 Natural human interferon β activity before and after spray-drying Relative activity (IU/A 280 unit) Remaining activity (%) Before spray-drying 4.11 ± 0.11 100 After spray-drying 3.14 ± 0.04 74.8 - After the spray-drying process, the natural human interferon β showed an interferon activity which was 74.8% of its activity prior to the spray-drying process, indicating that it can be spray-dried while maintaining its activity. These results are surprising because a similar natural human interferon β solution comprising a similar quantity of HSA will start deactivating at approximately 55° C., with complete deactivation occuring at 70° C.
- The dry powder obtained by the process of this invention was subjected to platinum coating and the shape of its grains was examined using a field emission scan electron microscope (model S-8000, manufactured by Hitachi Co.). Approximately 90% of the grains examined were grains with relatively smooth and large dents and protrusions in the grain surface, and with a grain diameter of approximately 10 μm. In addition, the resulting powder exhibited a moisture content of 5.6 wt % using the Karl Fischer method (coulometric titration Moisturemeter CA-06, manufactured by Mitsubishi Kasei Co.).
- This example sets forth a method for preparing an IFN/HSA/mannitol composition.
- Approximately 100 ml of 10 mM sodium chloride solution of natural human interferon comprising 150 mg/ml mannitol and approximately 2 mg/ml human serum albumin (HSA) were prepared. The proportion of the mannitol to the total solutes in this solution composition was approximately 90 wt %.
- The above solution was spray-dried using the same method and the same conditions as in Example IV, and the interferon activity of the dry powder obtained was measured using the same method as in Example IV. The results are shown in Table 2.
TABLE 2 Natural human interferon β activity before and after spray-drying Relative activity (IU/A 280 unit) Remaining activity (%) Before spray-drying 5.59 ± 0.51 100 After spray-drying 4.53 ± 0.13 81.0 - After the spray-drying process, the natural human interferon β maintained 81.0% of its activity compared with its activity prior to the spray-drying process. As in Example IV, these results are surprising because a similar aqueous solution of the same quantity of natural human interferon β, HSA and mannitol started to deactivate at approximately 55° C., with almost complete deactivation occurring at 70° C.
- While the IFN-based powder from Example IV and V are dispersible, the powder obtained from Example V was more readily dispersed than the powder obtained in Example IV. When the grain shape was examined by subjecting the powder to platinum coating and using a field emission scan electron microscope (model S-8000, manufactured by Hitachi Co.), the grains were found to have a size similar to those of Example IV but a shape more IS rounded compares with the powder particles obtained in Example IV. In addition, when the distribution of the grain diameter of the powder vas measured by dispersing it in ethanol anhydride and using a granulation analyzer (Microtrac FRA, manufactured by Nikkiso Co.), it was found that approximately 90% of the grains were distributed within the range of 1.6 to 9.3 μm. The moisture content was 0.74% wt, as measured by the Karl Fischer method of Example IV.
- All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
- The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.
Claims (26)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/245,704 US20030072718A1 (en) | 1994-05-18 | 2002-09-18 | Methods and compositions for the dry powder formulation of interferons |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24603494A | 1994-05-18 | 1994-05-18 | |
US08/737,724 US6231851B1 (en) | 1994-05-18 | 1995-05-15 | Methods and compositions for the dry powder formulation of interferons |
US09/444,116 US6123936A (en) | 1994-05-18 | 1999-11-22 | Methods and compositions for the dry powder formulation of interferons |
US09/506,426 US6479049B1 (en) | 1994-05-18 | 2000-02-17 | Methods and compositions for the dry powder formulation of interferons |
US10/245,704 US20030072718A1 (en) | 1994-05-18 | 2002-09-18 | Methods and compositions for the dry powder formulation of interferons |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/506,426 Continuation US6479049B1 (en) | 1994-05-18 | 2000-02-17 | Methods and compositions for the dry powder formulation of interferons |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030072718A1 true US20030072718A1 (en) | 2003-04-17 |
Family
ID=22929067
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/737,724 Expired - Fee Related US6231851B1 (en) | 1992-07-08 | 1995-05-15 | Methods and compositions for the dry powder formulation of interferons |
US09/444,116 Expired - Fee Related US6123936A (en) | 1994-05-18 | 1999-11-22 | Methods and compositions for the dry powder formulation of interferons |
US09/506,426 Expired - Fee Related US6479049B1 (en) | 1994-05-18 | 2000-02-17 | Methods and compositions for the dry powder formulation of interferons |
US10/245,704 Abandoned US20030072718A1 (en) | 1994-05-18 | 2002-09-18 | Methods and compositions for the dry powder formulation of interferons |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/737,724 Expired - Fee Related US6231851B1 (en) | 1992-07-08 | 1995-05-15 | Methods and compositions for the dry powder formulation of interferons |
US09/444,116 Expired - Fee Related US6123936A (en) | 1994-05-18 | 1999-11-22 | Methods and compositions for the dry powder formulation of interferons |
US09/506,426 Expired - Fee Related US6479049B1 (en) | 1994-05-18 | 2000-02-17 | Methods and compositions for the dry powder formulation of interferons |
Country Status (13)
Country | Link |
---|---|
US (4) | US6231851B1 (en) |
EP (1) | EP0759939B1 (en) |
JP (1) | JPH10500672A (en) |
KR (1) | KR100384353B1 (en) |
CN (1) | CN1073119C (en) |
AT (1) | ATE299892T1 (en) |
AU (1) | AU696387B2 (en) |
CA (1) | CA2190502A1 (en) |
DE (1) | DE69534318T2 (en) |
ES (1) | ES2245780T3 (en) |
MX (1) | MX9605717A (en) |
NZ (1) | NZ285664A (en) |
WO (1) | WO1995031479A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030086877A1 (en) * | 1992-07-08 | 2003-05-08 | Platz Robert M. | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments |
US20030113273A1 (en) * | 1996-06-17 | 2003-06-19 | Patton John S. | Methods and compositions for pulmonary delivery of insulin |
US20030171282A1 (en) * | 1992-09-29 | 2003-09-11 | Patton John S. | Pulmonary delivery of active fragments of parathyroid hormone |
US20040096400A1 (en) * | 1994-03-07 | 2004-05-20 | Patton John S. | Methods and compositions for the pulmonary delivery insulin |
US20040170568A1 (en) * | 1997-09-29 | 2004-09-02 | Weers Jeffry G. | Stabilized preparations for use in metered dose inhalers |
WO2005087253A2 (en) * | 2004-03-12 | 2005-09-22 | University Of Southampton | Interferon-beta for anti-virus therapy for respiratory diseases |
US20050276759A1 (en) * | 1994-12-02 | 2005-12-15 | Roser Bruce J | Solid dose delivery vehicle and methods of making same |
US8246934B2 (en) | 1997-09-29 | 2012-08-21 | Novartis Ag | Respiratory dispersion for metered dose inhalers comprising perforated microstructures |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US8709484B2 (en) | 2000-05-10 | 2014-04-29 | Novartis Ag | Phospholipid-based powders for drug delivery |
US8715623B2 (en) | 2001-12-19 | 2014-05-06 | Novartis Ag | Pulmonary delivery of aminoglycoside |
US8877162B2 (en) | 2000-05-10 | 2014-11-04 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery |
WO2014184352A1 (en) | 2013-05-17 | 2014-11-20 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof |
EP3011953A1 (en) | 2008-10-29 | 2016-04-27 | Ablynx N.V. | Stabilised formulations of single domain antigen binding molecules |
WO2017147248A1 (en) | 2016-02-24 | 2017-08-31 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
Families Citing this family (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
DE69534318T2 (en) * | 1994-05-18 | 2006-04-20 | Nektar Therapeutics, San Carlos | METHODS AND COMPOSITIONS FOR THE DRY PLANT FROM INTERFERONS |
US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
US5955108A (en) * | 1994-12-16 | 1999-09-21 | Quadrant Healthcare (Uk) Limited | Cross-linked microparticles and their use as therapeutic vehicles |
US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
CA2218074C (en) * | 1995-04-14 | 2002-10-08 | Mohammed Eljamal | Powdered pharmaceutical formulations having improved dispersibility |
US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
DE19539574A1 (en) | 1995-10-25 | 1997-04-30 | Boehringer Mannheim Gmbh | Preparations and processes for stabilizing biological materials by means of drying processes without freezing |
DE19544167A1 (en) * | 1995-11-17 | 1997-05-22 | Schering Ag | Use of interferon-ß for the treatment of bronchial carcinoma in radiation therapy |
TW403653B (en) * | 1995-12-25 | 2000-09-01 | Otsuka Pharma Co Ltd | Dry compositions |
GB9607035D0 (en) * | 1996-04-03 | 1996-06-05 | Andaris Ltd | Spray-dried microparticles as therapeutic vehicles |
EP0914096B1 (en) * | 1996-05-17 | 2003-08-13 | Elan Drug Delivery Limited | Microparticles and their use in wound therapy |
US20030035778A1 (en) * | 1997-07-14 | 2003-02-20 | Robert Platz | Methods and compositions for the dry powder formulation of interferon |
BR9811793A (en) | 1997-07-18 | 2000-09-26 | Infimed Inc | Biodegradable macromers for the controlled release of biologically active substances. |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
JP4574007B2 (en) * | 1998-04-28 | 2010-11-04 | メルク・セローノ・ソシエテ・アノニム | Polyol-IFN-beta complex |
US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
US6956021B1 (en) * | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
US6234167B1 (en) | 1998-10-14 | 2001-05-22 | Chrysalis Technologies, Incorporated | Aerosol generator and methods of making and using an aerosol generator |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
WO2001013891A2 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US7252840B1 (en) | 1999-08-25 | 2007-08-07 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles |
US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
US20010036481A1 (en) * | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
DE60044070D1 (en) | 1999-10-29 | 2010-05-06 | Novartis Ag | Dry powder compositions with improved dispersity |
ATE358171T1 (en) * | 1999-12-24 | 2007-04-15 | Otsuka Pharma Co Ltd | DRY COMPOSITION CONTAINING HYDROPHOBIC AMINO ACIDS |
MY136453A (en) * | 2000-04-27 | 2008-10-31 | Philip Morris Usa Inc | "improved method and apparatus for generating an aerosol" |
US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
AU2440802A (en) * | 2000-10-18 | 2002-04-29 | Massachusetts Inst Technology | Methods and products related to pulmonary delivery of polysaccharides |
US7544354B2 (en) | 2000-10-27 | 2009-06-09 | Novartis Vaccines And Diagnostics | Methods of protein purification and recovery |
US6994847B2 (en) | 2000-11-07 | 2006-02-07 | Chiron Corporation | Stabilized interferon compositions |
ATE355849T1 (en) * | 2000-12-21 | 2007-03-15 | Nektar Therapeutics | STORAGE-Stable POWDER COMPOSITIONS WITH INTERLEUKIN-4 RECEPTOR |
US6501052B2 (en) | 2000-12-22 | 2002-12-31 | Chrysalis Technologies Incorporated | Aerosol generator having multiple heating zones and methods of use thereof |
US7077130B2 (en) * | 2000-12-22 | 2006-07-18 | Chrysalis Technologies Incorporated | Disposable inhaler system |
US6799572B2 (en) * | 2000-12-22 | 2004-10-05 | Chrysalis Technologies Incorporated | Disposable aerosol generator system and methods for administering the aerosol |
US6701921B2 (en) * | 2000-12-22 | 2004-03-09 | Chrysalis Technologies Incorporated | Aerosol generator having heater in multilayered composite and method of use thereof |
JP2004516304A (en) * | 2000-12-22 | 2004-06-03 | アスペン・エアロジエルズ・インコーポレーテツド | Airgel powder containing therapeutic agent |
US6491233B2 (en) | 2000-12-22 | 2002-12-10 | Chrysalis Technologies Incorporated | Vapor driven aerosol generator and method of use thereof |
US6681998B2 (en) | 2000-12-22 | 2004-01-27 | Chrysalis Technologies Incorporated | Aerosol generator having inductive heater and method of use thereof |
US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
EP2080771A3 (en) | 2001-02-27 | 2010-01-06 | Maxygen Aps | New interferon beta-like molecules |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
EG24184A (en) | 2001-06-15 | 2008-10-08 | Otsuka Pharma Co Ltd | Dry powder inhalation system for transpulmonary |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
US6568390B2 (en) | 2001-09-21 | 2003-05-27 | Chrysalis Technologies Incorporated | Dual capillary fluid vaporizing device |
US6640050B2 (en) | 2001-09-21 | 2003-10-28 | Chrysalis Technologies Incorporated | Fluid vaporizing device having controlled temperature profile heater/capillary tube |
US7118915B2 (en) * | 2001-09-27 | 2006-10-10 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
WO2003035095A1 (en) * | 2001-10-19 | 2003-05-01 | Maxim Pharmaceuticals, Inc. | Use of histamine to treat liver disease |
TW200300696A (en) | 2001-11-01 | 2003-06-16 | Inhale Therapeutic Syst | Spray drying methods and related compositions |
WO2003043574A2 (en) | 2001-11-19 | 2003-05-30 | Becton, Dickinson And Company | Pharmaceutical compositions in particulate form |
JP4368198B2 (en) * | 2001-11-20 | 2009-11-18 | アルカーメス,インコーポレイテッド | Improved particulate composition for pulmonary delivery |
US20030129250A1 (en) * | 2001-11-20 | 2003-07-10 | Advanced Inhalation Research Inc. | Particulate compositions for improving solubility of poorly soluble agents |
US6804458B2 (en) | 2001-12-06 | 2004-10-12 | Chrysalis Technologies Incorporated | Aerosol generator having heater arranged to vaporize fluid in fluid passage between bonded layers of laminate |
US6681769B2 (en) | 2001-12-06 | 2004-01-27 | Crysalis Technologies Incorporated | Aerosol generator having a multiple path heater arrangement and method of use thereof |
US6701922B2 (en) | 2001-12-20 | 2004-03-09 | Chrysalis Technologies Incorporated | Mouthpiece entrainment airflow control for aerosol generators |
US20060188451A1 (en) * | 2001-12-21 | 2006-08-24 | Aspen Aerogels, Inc. | Aerogel based pharmaceutical formulations |
JP4681231B2 (en) | 2002-03-20 | 2011-05-11 | マンカインド コーポレイション | Inhaler |
AU2003225182B2 (en) * | 2002-04-25 | 2009-02-26 | Momenta Pharmaceuticals, Inc. | Methods and products for mucosal delivery |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
CA2494155C (en) * | 2002-08-22 | 2011-05-03 | Nutrition 21, Inc. | Arginine silicate inositol complex and use thereof |
AU2003285776A1 (en) * | 2002-12-13 | 2004-07-09 | Otsuka Pharmaceutical Co., Ltd. | FREEZE-DRIED INTERFERON-Gamma COMPOSITION FOR TRANSPULMONARY ADMINISTRATION AND INHALATION SYSTEM THEREFOR |
US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
ITMI20022748A1 (en) * | 2002-12-23 | 2004-06-24 | Eurand Int | STABILIZED SOLID DISPERSIONS OF DRUG IN AN ORGANIC CAREER AND PROCEDURE FOR THEIR PREPARATION. |
WO2004060343A1 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Antibody-containing particles and compositions |
CA2526222A1 (en) * | 2003-05-16 | 2004-12-02 | Arriva Pharmaceuticals, Inc. | Treatment of respiratory disease associated with matrix metalloprotease inhibitors |
US20050037047A1 (en) * | 2003-08-11 | 2005-02-17 | Young-Ho Song | Medical devices comprising spray dried microparticles |
CA2540699A1 (en) * | 2003-10-01 | 2005-04-14 | Momenta Pharmaceuticals, Inc. | Polysaccharides for pulmonary delivery of active agents |
WO2005060960A2 (en) * | 2003-12-11 | 2005-07-07 | Maxim Pharmaceuticals, Inc. | Use of histamine to treat bone disease |
CA2562585A1 (en) | 2004-04-23 | 2005-11-10 | Cydex, Inc. | Dpi formulation containing sulfoalkyl ether cyclodextrin |
US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
US7611709B2 (en) | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
US7723306B2 (en) | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
WO2005123113A2 (en) * | 2004-06-14 | 2005-12-29 | Intermune, Inc. | Interferon compositions and methods of use thereof |
RU2389477C2 (en) | 2004-06-18 | 2010-05-20 | Новартис Ваксинз Энд Дайагностикс Инк. | Methods of treating endobronchial diseases |
JP2008503586A (en) | 2004-06-21 | 2008-02-07 | ネクター セラピューティクス | Compositions, methods and systems comprising amphotericin B |
US8513204B2 (en) | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
EP1786784B1 (en) | 2004-08-20 | 2010-10-27 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
DK2322180T3 (en) | 2004-08-23 | 2015-06-15 | Mannkind Corp | Diketopiperazinsalte for drug delivery |
WO2006079121A2 (en) * | 2005-01-19 | 2006-07-27 | Avigenics, Inc. | Methods of treating disease with glycosylated interferon |
WO2007019554A2 (en) * | 2005-08-08 | 2007-02-15 | Momenta Pharmaceuticals, Inc. | Polysaccharides for delivery of active agents |
KR101643478B1 (en) | 2005-09-14 | 2016-07-27 | 맨카인드 코포레이션 | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US8105571B2 (en) | 2005-09-20 | 2012-01-31 | New York University | Method of treating pulmonary disease with interferons |
US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
MX360812B (en) * | 2006-02-22 | 2018-11-16 | Mannkind Corp | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent. |
DE102006014714B3 (en) * | 2006-03-30 | 2007-05-16 | Draegerwerk Ag | Electrochemical sensor for gas detection has aromatic or alphatic acid carbonic acids in alkali electrolyte solution |
DE102006030164A1 (en) * | 2006-06-29 | 2008-01-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative powders |
JP2010508069A (en) | 2006-10-25 | 2010-03-18 | ノバルティス アーゲー | Powder disperser, method of manufacturing and using the device, component used in the device and other devices |
PL2425820T3 (en) | 2007-02-11 | 2015-08-31 | Map Pharmaceuticals Inc | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
WO2008107908A1 (en) * | 2007-03-05 | 2008-09-12 | Cadila Healthcare Limited | Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant |
US8268354B2 (en) | 2007-11-07 | 2012-09-18 | Aridis Pharmaceuticals | Sonic low pressure spray drying |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
KR101655053B1 (en) | 2008-06-13 | 2016-09-07 | 맨카인드 코포레이션 | A dry powder inhaler and system for drug delivery |
ES2904623T3 (en) | 2008-06-20 | 2022-04-05 | Mannkind Corp | Interactive device to establish a real-time profile of inhalation efforts |
TWI532497B (en) | 2008-08-11 | 2016-05-11 | 曼凱公司 | Use of ultrarapid acting insulin |
JP2012509922A (en) * | 2008-11-27 | 2012-04-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | New powdered crystalline inhalant |
PT2379511E (en) | 2008-12-29 | 2015-02-27 | Mannkind Corp | Substituted diketopiperazine analogs for use as drug delivery agents |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
DK2405963T3 (en) | 2009-03-11 | 2013-12-16 | Mannkind Corp | DEVICE, SYSTEM AND PROCEDURE FOR MEASURING RESISTANCE IN AN INHALATOR |
EP3552602A1 (en) | 2009-03-18 | 2019-10-16 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
KR101875969B1 (en) | 2009-06-12 | 2018-07-06 | 맨카인드 코포레이션 | Diketopiperazine microparticles with defined specific surface areas |
US9016147B2 (en) | 2009-11-03 | 2015-04-28 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
DK2990798T3 (en) | 2009-12-07 | 2019-12-02 | Pieris Pharmaceuticals Gmbh | MUTEINS OF HUMAN LIPOCALIN 2 (LCN2, HNGAL) WITH AFFINITY FOR A SPECIFIC TARGET |
PL2528617T3 (en) | 2010-01-28 | 2016-09-30 | Interleukin-2 or interferon-alpha for use in treating nicotine or food addiction | |
EP2582421A1 (en) | 2010-06-21 | 2013-04-24 | MannKind Corporation | Dry powder drug delivery system and methods |
ES2645769T3 (en) | 2011-01-05 | 2017-12-07 | Hospira, Inc. | Vancomycin spray drying |
CA2767773C (en) * | 2011-02-11 | 2015-11-24 | Grain Processing Corporation | Composition comprising a salt and a crystallization interrupter |
AU2012236150B2 (en) | 2011-04-01 | 2016-03-31 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US9572774B2 (en) | 2011-05-19 | 2017-02-21 | Savara Inc. | Dry powder vancomycin compositions and associated methods |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
CA2852536A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
RU2635482C2 (en) | 2011-12-30 | 2017-11-13 | Грайфолз, С.А. | Alpha-1 proteinase inhibitor for delay of beginning or progress of pulmonary exacerbations |
CN102727467B (en) * | 2012-07-07 | 2014-03-12 | 北京三元基因工程有限公司 | Dry powder inhalant of interferon alpha |
CN102727469B (en) * | 2012-07-07 | 2013-12-11 | 北京三元基因工程有限公司 | Dry powder inhalant of interferon alpha |
CN102727468B (en) * | 2012-07-07 | 2014-03-12 | 北京三元基因工程有限公司 | Dry powder inhaler of interferon alpha |
CN102716105B (en) * | 2012-07-07 | 2014-04-16 | 北京三元基因工程有限公司 | Dry powder inhalant of interferon Alpha |
JP6312262B2 (en) | 2012-07-12 | 2018-04-18 | マンカインド コーポレイション | Dry powder drug delivery system |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
US10526384B2 (en) | 2012-11-19 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof |
KR102391750B1 (en) | 2013-03-15 | 2022-04-28 | 맨카인드 코포레이션 | Microcrystalline diketopiperazine compositions and methods |
CN104043104B (en) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | The spray dried powder and its industrialized process for preparing of hydrochloric vancomycin |
CN104116712B (en) * | 2013-04-23 | 2017-06-20 | 北京大学 | A kind of hollow property nanometer aggregated particle of interferon albumin for pulmonary administration |
CN105451716A (en) | 2013-07-18 | 2016-03-30 | 曼金德公司 | Heat-stable dry powder pharmaceutical compositions and methods |
CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
CA2936611A1 (en) | 2014-01-13 | 2015-07-16 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
SG11201609274SA (en) | 2014-05-22 | 2016-12-29 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US20170333359A1 (en) * | 2014-10-20 | 2017-11-23 | Rx Analytic, Inc | A drug-containing micro particle |
CN107207574A (en) | 2015-01-28 | 2017-09-26 | 皮里斯制药有限公司 | The specific novel protein of angiogenesis |
US11191735B2 (en) | 2015-03-13 | 2021-12-07 | Nutrition 21, Llc | Arginine silicate for periodontal disease |
WO2016169571A1 (en) * | 2015-04-20 | 2016-10-27 | Ghaleb Haider Abbas | Pharmaceutical product for treatment & prophylaxis of viral/ microbial infection |
WO2016177762A1 (en) | 2015-05-04 | 2016-11-10 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
WO2016177802A1 (en) | 2015-05-04 | 2016-11-10 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
MX2017014730A (en) | 2015-05-18 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3). |
LT3298030T (en) | 2015-05-18 | 2023-02-27 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
US20170135969A1 (en) | 2015-11-12 | 2017-05-18 | Jds Therapeutics, Llc | Topical arginine-silicate-inositol for wound healing |
BR112018010887A2 (en) | 2015-11-30 | 2018-11-21 | Pieris Australia Pty Ltd | fusion polypeptide |
TW201725212A (en) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | Novel proteins specific for calcitonin gene-related peptide |
US10010294B2 (en) | 2016-02-01 | 2018-07-03 | Incarda Therapeutics, Inc. | Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation |
WO2018045244A1 (en) | 2016-09-01 | 2018-03-08 | Jds Therapeutics, Llc | Magnesium biotinate compositions and methods of use |
CA3060702A1 (en) | 2017-05-10 | 2018-11-15 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
CA3118583A1 (en) | 2018-11-02 | 2020-05-07 | Nutrition 21, Llc | Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers |
US11020384B2 (en) | 2019-08-01 | 2021-06-01 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
AU2020407071A1 (en) | 2019-12-16 | 2022-07-07 | Nutrition 21, Llc | Methods of production of arginine-silicate complexes |
EP4203928A1 (en) * | 2020-08-26 | 2023-07-05 | Cila Therapeutic Inc. | Inhalable therapeutic agents |
EP4304582A1 (en) | 2021-03-12 | 2024-01-17 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
Citations (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1855591A (en) * | 1926-02-03 | 1932-04-26 | Wallerstein Co Inc | Invertase preparation and method of making the same |
US3362405A (en) * | 1964-04-06 | 1968-01-09 | Hamilton O. Hazel | Method and apparatus for admixing gas with solid particles |
US3555717A (en) * | 1968-10-24 | 1971-01-19 | Victor Comptometer Corp | Artificial fishing lure |
US3557717A (en) * | 1968-05-17 | 1971-01-26 | Gen Mills Inc | Process for making candy floss |
US3632357A (en) * | 1969-07-29 | 1972-01-04 | Standard Brands Inc | Method of producing hard candy |
US3655442A (en) * | 1969-08-27 | 1972-04-11 | California & Hawaiian Sugar | Method of making sugar and sugar products |
US3937668A (en) * | 1970-07-15 | 1976-02-10 | Ilse Zolle | Method for incorporating substances into protein microspheres |
US3948263A (en) * | 1974-08-14 | 1976-04-06 | Minnesota Mining And Manufacturing Company | Ballistic animal implant |
US3956330A (en) * | 1973-06-27 | 1976-05-11 | American Cyanamid Company | N,N-diethyl-4-methyl-1-pi-perazinecarboxamide pamoate |
US4192309A (en) * | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
US4244949A (en) * | 1978-04-06 | 1981-01-13 | The Population Council, Inc. | Manufacture of long term contraceptive implant |
US4253468A (en) * | 1978-08-14 | 1981-03-03 | Steven Lehmbeck | Nebulizer attachment |
US4327077A (en) * | 1981-05-29 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4327076A (en) * | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4326524A (en) * | 1980-09-30 | 1982-04-27 | Minnesota Mining And Manufacturing Company | Solid dose ballistic projectile |
US4371557A (en) * | 1981-01-21 | 1983-02-01 | General Foods Corporation | Maintenance of protein quality in foods containing reducing sugars |
US4503035A (en) * | 1978-11-24 | 1985-03-05 | Hoffmann-La Roche Inc. | Protein purification process and product |
US4588744A (en) * | 1978-09-19 | 1986-05-13 | Mchugh John E | Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide |
US4590206A (en) * | 1981-07-24 | 1986-05-20 | Fisons Plc | Inhalation pharmaceuticals |
US4591522A (en) * | 1985-01-04 | 1986-05-27 | W. R. Grace & Co. | Liquid photopolymers curable to fire-retardant, hydrolysis resistant compositions |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4739754A (en) * | 1986-05-06 | 1988-04-26 | Shaner William T | Suction resistant inhalator |
US4812444A (en) * | 1985-12-26 | 1989-03-14 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Dehydration of hydrous matter using anhydrous glycosylfructose |
US4811731A (en) * | 1985-07-30 | 1989-03-14 | Glaxo Group Limited | Devices for administering medicaments to patients |
US4814436A (en) * | 1985-12-16 | 1989-03-21 | Ss Pharmaceutical Co., Ltd. | Derivative of α, α-trehalose and a process for preparing the same |
US4819629A (en) * | 1986-10-28 | 1989-04-11 | Siemens Aktiengesellschaft | Method and apparatus for delivering aerosol to the airways and/or lungs of a patient |
US4824938A (en) * | 1984-06-06 | 1989-04-25 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Water-soluble dry solid containing proteinaceous bioactive substance |
US4830858A (en) * | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
US4891319A (en) * | 1985-07-09 | 1990-01-02 | Quadrant Bioresources Limited | Protection of proteins and the like |
US4895719A (en) * | 1985-05-22 | 1990-01-23 | Liposome Technology, Inc. | Method and apparatus for administering dehydrated liposomes by inhalation |
US4906463A (en) * | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
US4907583A (en) * | 1986-03-07 | 1990-03-13 | Aktiebolaget Draco | Device in powder inhalators |
US4908214A (en) * | 1987-07-23 | 1990-03-13 | Synthelabo | Pharmaceutical tablet for the treatment of uraemia |
US4984158A (en) * | 1988-10-14 | 1991-01-08 | Hillsman Dean | Metered dose inhaler biofeedback training and evaluation system |
US4988683A (en) * | 1987-03-04 | 1991-01-29 | Jerome Corbiere | New pharmaceutical compositions for the buccal tract and process for their preparation |
US5006343A (en) * | 1988-12-29 | 1991-04-09 | Benson Bradley J | Pulmonary administration of pharmaceutically active substances |
US5011678A (en) * | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
US5013557A (en) * | 1989-10-03 | 1991-05-07 | Warner-Lambert Company | Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same |
US5017372A (en) * | 1986-04-14 | 1991-05-21 | Medicis Corporation | Method of producing antibody-fortified dry whey |
US5089181A (en) * | 1987-02-24 | 1992-02-18 | Vestar, Inc. | Method of dehydrating vesicle preparations for long term storage |
US5098893A (en) * | 1989-02-16 | 1992-03-24 | Pafra Limited | Storage of materials |
US5112596A (en) * | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5112598A (en) * | 1988-05-04 | 1992-05-12 | Hermes Fabrik Pharmazeutischer Preparate Franz Gradinger Gmbh & Co. Kg | Vitamin a aerosol-inhalate preparations |
US5113855A (en) * | 1990-02-14 | 1992-05-19 | Newhouse Michael T | Powder inhaler |
US5182097A (en) * | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
US5200399A (en) * | 1990-09-14 | 1993-04-06 | Boyce Thompson Institute For Plant Research, Inc. | Method of protecting biological materials from destructive reactions in the dry state |
US5202333A (en) * | 1989-11-28 | 1993-04-13 | Syntex (U.S.A.) Inc. | Tricyclic 5-HT3 receptor antagonists |
US5204108A (en) * | 1987-10-10 | 1993-04-20 | Danbiosyst Uk Ltd. | Transmucosal formulations of low molecular weight peptide drugs |
US5284656A (en) * | 1991-03-15 | 1994-02-08 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US5306506A (en) * | 1990-07-11 | 1994-04-26 | Eurand International S.P.A. | Pharmaceutical composition for rapid suspension in water |
US5309900A (en) * | 1991-03-21 | 1994-05-10 | Paul Ritzau Pari-Werk Gmbh | Atomizer particularly for use in devices for inhalation therapy |
US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5312909A (en) * | 1990-03-28 | 1994-05-17 | Gist Brocades, N.V. | Recombinant DNA encoding neutral trehalase |
US5380473A (en) * | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
US5384133A (en) * | 1986-08-11 | 1995-01-24 | Innovata Biomed Limited | Pharmaceutical formulations comprising microcapsules |
US5387431A (en) * | 1991-10-25 | 1995-02-07 | Fuisz Technologies Ltd. | Saccharide-based matrix |
US5403861A (en) * | 1991-02-08 | 1995-04-04 | Cambridge Neuroscience, Inc. | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers |
US5404871A (en) * | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
US5482927A (en) * | 1991-02-20 | 1996-01-09 | Massachusetts Institute Of Technology | Controlled released microparticulate delivery system for proteins |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5518709A (en) * | 1991-04-10 | 1996-05-21 | Andaris Limited | Preparation of diagnostic agents |
US5591453A (en) * | 1994-07-27 | 1997-01-07 | The Trustees Of The University Of Pennsylvania | Incorporation of biologically active molecules into bioactive glasses |
US5607915A (en) * | 1992-09-29 | 1997-03-04 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
US5611344A (en) * | 1996-03-05 | 1997-03-18 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
US5618786A (en) * | 1987-04-30 | 1997-04-08 | Cooper Laboratories, Inc. | Aerosolization of protein therapeutic agent |
US5621094A (en) * | 1990-05-14 | 1997-04-15 | Quadrant Holdings Cambridge Limited | Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol |
US5631225A (en) * | 1994-10-13 | 1997-05-20 | Novo Nordisk A/S | Pharmaceutical formulation |
US5705482A (en) * | 1995-01-13 | 1998-01-06 | Novo Nordisk A/S | Pharmaceutical formulation |
US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5728574A (en) * | 1993-07-19 | 1998-03-17 | Zeneca Limited | Viability of bacterial dried cells |
US5733555A (en) * | 1994-05-10 | 1998-03-31 | American Home Products Corporation | Modified live BRSV vaccine |
US5891873A (en) * | 1994-04-13 | 1999-04-06 | Quadrant Holdings Cambridge Limited | Use of maillard reaction inhibitors for the treatment of amyloidosis-based disease |
US6013638A (en) * | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
US6019968A (en) * | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
US6060069A (en) * | 1991-05-20 | 2000-05-09 | Dura Pharmaceuticals, Inc. | Pulmonary delivery of pharmaceuticals |
US6187344B1 (en) * | 1995-04-14 | 2001-02-13 | Inhale Therapeutic Systems | Powdered pharmaceutical formulations having improved dispersibility |
US6190859B1 (en) * | 1995-04-17 | 2001-02-20 | The United States Of America As Represented By The Secretary Of The Army | Method and kit for detection of dengue virus |
US6231851B1 (en) * | 1994-05-18 | 2001-05-15 | Inhale Therapeutic Systems | Methods and compositions for the dry powder formulation of interferons |
US6365190B1 (en) * | 1996-12-31 | 2002-04-02 | Inhale Therapeutic Systems, Inc. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
US6372258B1 (en) * | 1992-07-08 | 2002-04-16 | Inhale Therapeutic Systems | Methods of spray-drying a drug and a hydrophobic amino acid |
US6503411B1 (en) * | 1995-04-28 | 2003-01-07 | Inhale Therapeutic Systems, Inc. | Stable compositions |
US6509006B1 (en) * | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
US6514496B1 (en) * | 1995-04-14 | 2003-02-04 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6518239B1 (en) * | 1999-10-29 | 2003-02-11 | Inhale Therapeutic Systems, Inc. | Dry powder compositions having improved dispersivity |
US20030035778A1 (en) * | 1997-07-14 | 2003-02-20 | Robert Platz | Methods and compositions for the dry powder formulation of interferon |
US20030086877A1 (en) * | 1992-07-08 | 2003-05-08 | Platz Robert M. | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments |
US20030092666A1 (en) * | 1993-04-07 | 2003-05-15 | Mohammed Eljamal | Compositions and methods for nucleic acid delivery to the lung |
US6565871B2 (en) * | 1994-12-02 | 2003-05-20 | Elan Drug Delivery Ltd. | Solid dose delivery vehicle and methods of making same |
US6569406B2 (en) * | 2000-08-07 | 2003-05-27 | Nektar Therapeutics | Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation |
US6681767B1 (en) * | 1991-07-02 | 2004-01-27 | Nektar Therapeutics | Method and device for delivering aerosolized medicaments |
US6685967B1 (en) * | 1994-03-07 | 2004-02-03 | Nektar Therapeutics | Methods and compositions for pulmonary delivery of insulin |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59163313A (en) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | Peptide hormone composition for nasal administration |
US4847079A (en) * | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
US5004605A (en) | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
US4906476A (en) * | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
JPH05963A (en) * | 1990-04-13 | 1993-01-08 | Toray Ind Inc | Polypeptide composition |
WO1991016882A1 (en) | 1990-05-08 | 1991-11-14 | Liposome Technology, Inc. | Direct spray-dried drug/lipid powder composition |
DE69230613T2 (en) * | 1991-07-02 | 2000-12-28 | Inhale Inc | METHOD AND DEVICE FOR DISPENSING MEDICINES IN AEROSOL FORM |
ATE146359T1 (en) | 1992-01-21 | 1997-01-15 | Stanford Res Inst Int | IMPROVED METHOD FOR PRODUCING MICRONIZED POLYPEPTIDE DRUGS |
US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
-
1995
- 1995-05-15 DE DE69534318T patent/DE69534318T2/en not_active Revoked
- 1995-05-15 ES ES95919181T patent/ES2245780T3/en not_active Expired - Lifetime
- 1995-05-15 CA CA002190502A patent/CA2190502A1/en not_active Abandoned
- 1995-05-15 AT AT95919181T patent/ATE299892T1/en not_active IP Right Cessation
- 1995-05-15 KR KR1019960706515A patent/KR100384353B1/en not_active IP Right Cessation
- 1995-05-15 JP JP7529809A patent/JPH10500672A/en active Pending
- 1995-05-15 WO PCT/US1995/006008 patent/WO1995031479A1/en active IP Right Grant
- 1995-05-15 MX MX9605717A patent/MX9605717A/en not_active IP Right Cessation
- 1995-05-15 AU AU25142/95A patent/AU696387B2/en not_active Ceased
- 1995-05-15 CN CN95193669A patent/CN1073119C/en not_active Expired - Fee Related
- 1995-05-15 NZ NZ285664A patent/NZ285664A/en not_active IP Right Cessation
- 1995-05-15 US US08/737,724 patent/US6231851B1/en not_active Expired - Fee Related
- 1995-05-15 EP EP95919181A patent/EP0759939B1/en not_active Revoked
-
1999
- 1999-11-22 US US09/444,116 patent/US6123936A/en not_active Expired - Fee Related
-
2000
- 2000-02-17 US US09/506,426 patent/US6479049B1/en not_active Expired - Fee Related
-
2002
- 2002-09-18 US US10/245,704 patent/US20030072718A1/en not_active Abandoned
Patent Citations (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1855591A (en) * | 1926-02-03 | 1932-04-26 | Wallerstein Co Inc | Invertase preparation and method of making the same |
US3362405A (en) * | 1964-04-06 | 1968-01-09 | Hamilton O. Hazel | Method and apparatus for admixing gas with solid particles |
US3557717A (en) * | 1968-05-17 | 1971-01-26 | Gen Mills Inc | Process for making candy floss |
US3555717A (en) * | 1968-10-24 | 1971-01-19 | Victor Comptometer Corp | Artificial fishing lure |
US3632357A (en) * | 1969-07-29 | 1972-01-04 | Standard Brands Inc | Method of producing hard candy |
US3655442A (en) * | 1969-08-27 | 1972-04-11 | California & Hawaiian Sugar | Method of making sugar and sugar products |
US3937668A (en) * | 1970-07-15 | 1976-02-10 | Ilse Zolle | Method for incorporating substances into protein microspheres |
US3956330A (en) * | 1973-06-27 | 1976-05-11 | American Cyanamid Company | N,N-diethyl-4-methyl-1-pi-perazinecarboxamide pamoate |
US3948263A (en) * | 1974-08-14 | 1976-04-06 | Minnesota Mining And Manufacturing Company | Ballistic animal implant |
US4244949A (en) * | 1978-04-06 | 1981-01-13 | The Population Council, Inc. | Manufacture of long term contraceptive implant |
US4253468A (en) * | 1978-08-14 | 1981-03-03 | Steven Lehmbeck | Nebulizer attachment |
US4192309A (en) * | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
US4588744A (en) * | 1978-09-19 | 1986-05-13 | Mchugh John E | Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide |
US4503035A (en) * | 1978-11-24 | 1985-03-05 | Hoffmann-La Roche Inc. | Protein purification process and product |
US4503035B1 (en) * | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
US4326524A (en) * | 1980-09-30 | 1982-04-27 | Minnesota Mining And Manufacturing Company | Solid dose ballistic projectile |
US4327076A (en) * | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4371557A (en) * | 1981-01-21 | 1983-02-01 | General Foods Corporation | Maintenance of protein quality in foods containing reducing sugars |
US4327077A (en) * | 1981-05-29 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4590206A (en) * | 1981-07-24 | 1986-05-20 | Fisons Plc | Inhalation pharmaceuticals |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4824938A (en) * | 1984-06-06 | 1989-04-25 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Water-soluble dry solid containing proteinaceous bioactive substance |
US4591522A (en) * | 1985-01-04 | 1986-05-27 | W. R. Grace & Co. | Liquid photopolymers curable to fire-retardant, hydrolysis resistant compositions |
US4830858A (en) * | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
US4895719A (en) * | 1985-05-22 | 1990-01-23 | Liposome Technology, Inc. | Method and apparatus for administering dehydrated liposomes by inhalation |
US4891319A (en) * | 1985-07-09 | 1990-01-02 | Quadrant Bioresources Limited | Protection of proteins and the like |
US4811731A (en) * | 1985-07-30 | 1989-03-14 | Glaxo Group Limited | Devices for administering medicaments to patients |
US4814436A (en) * | 1985-12-16 | 1989-03-21 | Ss Pharmaceutical Co., Ltd. | Derivative of α, α-trehalose and a process for preparing the same |
US4812444A (en) * | 1985-12-26 | 1989-03-14 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Dehydration of hydrous matter using anhydrous glycosylfructose |
US4907583A (en) * | 1986-03-07 | 1990-03-13 | Aktiebolaget Draco | Device in powder inhalators |
US5017372A (en) * | 1986-04-14 | 1991-05-21 | Medicis Corporation | Method of producing antibody-fortified dry whey |
US4739754A (en) * | 1986-05-06 | 1988-04-26 | Shaner William T | Suction resistant inhalator |
US5384133A (en) * | 1986-08-11 | 1995-01-24 | Innovata Biomed Limited | Pharmaceutical formulations comprising microcapsules |
US4819629A (en) * | 1986-10-28 | 1989-04-11 | Siemens Aktiengesellschaft | Method and apparatus for delivering aerosol to the airways and/or lungs of a patient |
US4906463A (en) * | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
US5089181A (en) * | 1987-02-24 | 1992-02-18 | Vestar, Inc. | Method of dehydrating vesicle preparations for long term storage |
US4988683A (en) * | 1987-03-04 | 1991-01-29 | Jerome Corbiere | New pharmaceutical compositions for the buccal tract and process for their preparation |
US5618786A (en) * | 1987-04-30 | 1997-04-08 | Cooper Laboratories, Inc. | Aerosolization of protein therapeutic agent |
US4908214A (en) * | 1987-07-23 | 1990-03-13 | Synthelabo | Pharmaceutical tablet for the treatment of uraemia |
US5204108A (en) * | 1987-10-10 | 1993-04-20 | Danbiosyst Uk Ltd. | Transmucosal formulations of low molecular weight peptide drugs |
US5112598A (en) * | 1988-05-04 | 1992-05-12 | Hermes Fabrik Pharmazeutischer Preparate Franz Gradinger Gmbh & Co. Kg | Vitamin a aerosol-inhalate preparations |
US4984158A (en) * | 1988-10-14 | 1991-01-08 | Hillsman Dean | Metered dose inhaler biofeedback training and evaluation system |
US5006343A (en) * | 1988-12-29 | 1991-04-09 | Benson Bradley J | Pulmonary administration of pharmaceutically active substances |
US5011678A (en) * | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
US5098893A (en) * | 1989-02-16 | 1992-03-24 | Pafra Limited | Storage of materials |
US5013557A (en) * | 1989-10-03 | 1991-05-07 | Warner-Lambert Company | Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same |
US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5202333A (en) * | 1989-11-28 | 1993-04-13 | Syntex (U.S.A.) Inc. | Tricyclic 5-HT3 receptor antagonists |
US5113855A (en) * | 1990-02-14 | 1992-05-19 | Newhouse Michael T | Powder inhaler |
US5312909A (en) * | 1990-03-28 | 1994-05-17 | Gist Brocades, N.V. | Recombinant DNA encoding neutral trehalase |
US5112596A (en) * | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5621094A (en) * | 1990-05-14 | 1997-04-15 | Quadrant Holdings Cambridge Limited | Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol |
US5306506A (en) * | 1990-07-11 | 1994-04-26 | Eurand International S.P.A. | Pharmaceutical composition for rapid suspension in water |
US5290765A (en) * | 1990-09-14 | 1994-03-01 | Boyce Thompson Institute For Plant Research, Inc. | Method of protecting biological materials from destructive reactions in the dry state |
US5200399A (en) * | 1990-09-14 | 1993-04-06 | Boyce Thompson Institute For Plant Research, Inc. | Method of protecting biological materials from destructive reactions in the dry state |
US5403861A (en) * | 1991-02-08 | 1995-04-04 | Cambridge Neuroscience, Inc. | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers |
US5182097A (en) * | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
US5482927A (en) * | 1991-02-20 | 1996-01-09 | Massachusetts Institute Of Technology | Controlled released microparticulate delivery system for proteins |
US5404871A (en) * | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
US5284656A (en) * | 1991-03-15 | 1994-02-08 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US5309900A (en) * | 1991-03-21 | 1994-05-10 | Paul Ritzau Pari-Werk Gmbh | Atomizer particularly for use in devices for inhalation therapy |
US5518709A (en) * | 1991-04-10 | 1996-05-21 | Andaris Limited | Preparation of diagnostic agents |
US6060069A (en) * | 1991-05-20 | 2000-05-09 | Dura Pharmaceuticals, Inc. | Pulmonary delivery of pharmaceuticals |
US6681767B1 (en) * | 1991-07-02 | 2004-01-27 | Nektar Therapeutics | Method and device for delivering aerosolized medicaments |
US6013638A (en) * | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
US5387431A (en) * | 1991-10-25 | 1995-02-07 | Fuisz Technologies Ltd. | Saccharide-based matrix |
US6673335B1 (en) * | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
US20030086877A1 (en) * | 1992-07-08 | 2003-05-08 | Platz Robert M. | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments |
US6509006B1 (en) * | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
US6372258B1 (en) * | 1992-07-08 | 2002-04-16 | Inhale Therapeutic Systems | Methods of spray-drying a drug and a hydrophobic amino acid |
US5607915A (en) * | 1992-09-29 | 1997-03-04 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
US5380473A (en) * | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
US20030092666A1 (en) * | 1993-04-07 | 2003-05-15 | Mohammed Eljamal | Compositions and methods for nucleic acid delivery to the lung |
US5728574A (en) * | 1993-07-19 | 1998-03-17 | Zeneca Limited | Viability of bacterial dried cells |
US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
US6685967B1 (en) * | 1994-03-07 | 2004-02-03 | Nektar Therapeutics | Methods and compositions for pulmonary delivery of insulin |
US5891873A (en) * | 1994-04-13 | 1999-04-06 | Quadrant Holdings Cambridge Limited | Use of maillard reaction inhibitors for the treatment of amyloidosis-based disease |
US6034080A (en) * | 1994-04-13 | 2000-03-07 | Quadrant Holdings Cambridge Limited | Use of Maillard reaction inhibitors for the treatment of amyloidosis-based disease |
US5733555A (en) * | 1994-05-10 | 1998-03-31 | American Home Products Corporation | Modified live BRSV vaccine |
US6231851B1 (en) * | 1994-05-18 | 2001-05-15 | Inhale Therapeutic Systems | Methods and compositions for the dry powder formulation of interferons |
US5591453A (en) * | 1994-07-27 | 1997-01-07 | The Trustees Of The University Of Pennsylvania | Incorporation of biologically active molecules into bioactive glasses |
US5631225A (en) * | 1994-10-13 | 1997-05-20 | Novo Nordisk A/S | Pharmaceutical formulation |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US6565871B2 (en) * | 1994-12-02 | 2003-05-20 | Elan Drug Delivery Ltd. | Solid dose delivery vehicle and methods of making same |
US20040052825A1 (en) * | 1994-12-02 | 2004-03-18 | Roser Bruce J. | Solid dose delivery vehicle and methods of making same |
US5705482A (en) * | 1995-01-13 | 1998-01-06 | Novo Nordisk A/S | Pharmaceutical formulation |
US6187344B1 (en) * | 1995-04-14 | 2001-02-13 | Inhale Therapeutic Systems | Powdered pharmaceutical formulations having improved dispersibility |
US20030068279A1 (en) * | 1995-04-14 | 2003-04-10 | Platz Robert M. | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments |
US6514496B1 (en) * | 1995-04-14 | 2003-02-04 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6019968A (en) * | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6358530B1 (en) * | 1995-04-14 | 2002-03-19 | Inhale Therapeutic Systems, Inc. | Powdered pharmaceutical formulations having improved dispersibility |
US6190859B1 (en) * | 1995-04-17 | 2001-02-20 | The United States Of America As Represented By The Secretary Of The Army | Method and kit for detection of dengue virus |
US6503411B1 (en) * | 1995-04-28 | 2003-01-07 | Inhale Therapeutic Systems, Inc. | Stable compositions |
US5611344A (en) * | 1996-03-05 | 1997-03-18 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
US6365190B1 (en) * | 1996-12-31 | 2002-04-02 | Inhale Therapeutic Systems, Inc. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
US20030035778A1 (en) * | 1997-07-14 | 2003-02-20 | Robert Platz | Methods and compositions for the dry powder formulation of interferon |
US6518239B1 (en) * | 1999-10-29 | 2003-02-11 | Inhale Therapeutic Systems, Inc. | Dry powder compositions having improved dispersivity |
US6569406B2 (en) * | 2000-08-07 | 2003-05-27 | Nektar Therapeutics | Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030086877A1 (en) * | 1992-07-08 | 2003-05-08 | Platz Robert M. | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments |
US20080075782A1 (en) * | 1992-09-29 | 2008-03-27 | Patton John S | Pulmonary delivery of active fragments parathyroid hormone |
US20030171282A1 (en) * | 1992-09-29 | 2003-09-11 | Patton John S. | Pulmonary delivery of active fragments of parathyroid hormone |
US20040096400A1 (en) * | 1994-03-07 | 2004-05-20 | Patton John S. | Methods and compositions for the pulmonary delivery insulin |
US20090203576A1 (en) * | 1994-03-07 | 2009-08-13 | Patton John S | Methods and compositons for pulmonary delivery of insulin |
US7780991B2 (en) | 1994-12-02 | 2010-08-24 | Quadrant Drug Delivery Limited | Solid dose delivery vehicle and methods of making same |
US7744925B2 (en) | 1994-12-02 | 2010-06-29 | Quadrant Drug Delivery Limited | Solid dose delivery vehicle and methods of making same |
US20050276759A1 (en) * | 1994-12-02 | 2005-12-15 | Roser Bruce J | Solid dose delivery vehicle and methods of making same |
US20050276846A1 (en) * | 1994-12-02 | 2005-12-15 | Roser Bruce J | Solid dose delivery vehicle and methods of making same |
US20050276845A1 (en) * | 1994-12-02 | 2005-12-15 | Roser Bruce J | Solid dose delivery vehicle and methods of making same |
US7785631B2 (en) | 1994-12-02 | 2010-08-31 | Quadrant Drug Delivery Limited | Solid dose delivery vehicle and methods of making same |
US20030113273A1 (en) * | 1996-06-17 | 2003-06-19 | Patton John S. | Methods and compositions for pulmonary delivery of insulin |
US9554993B2 (en) | 1997-09-29 | 2017-01-31 | Novartis Ag | Pulmonary delivery particles comprising an active agent |
US8246934B2 (en) | 1997-09-29 | 2012-08-21 | Novartis Ag | Respiratory dispersion for metered dose inhalers comprising perforated microstructures |
US20040170568A1 (en) * | 1997-09-29 | 2004-09-02 | Weers Jeffry G. | Stabilized preparations for use in metered dose inhalers |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US8709484B2 (en) | 2000-05-10 | 2014-04-29 | Novartis Ag | Phospholipid-based powders for drug delivery |
US9439862B2 (en) | 2000-05-10 | 2016-09-13 | Novartis Ag | Phospholipid-based powders for drug delivery |
US8877162B2 (en) | 2000-05-10 | 2014-11-04 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery |
US9421166B2 (en) | 2001-12-19 | 2016-08-23 | Novartis Ag | Pulmonary delivery of aminoglycoside |
US8715623B2 (en) | 2001-12-19 | 2014-05-06 | Novartis Ag | Pulmonary delivery of aminoglycoside |
WO2005087253A3 (en) * | 2004-03-12 | 2005-11-24 | Univ Southampton | Interferon-beta for anti-virus therapy for respiratory diseases |
US20090257980A1 (en) * | 2004-03-12 | 2009-10-15 | Donna Elizabeth Davies | Anti-virus therapy for respiratory diseases |
US8273342B2 (en) | 2004-03-12 | 2012-09-25 | University Of Southampton | Anti-virus therapy for respiratory diseases |
US9089535B2 (en) | 2004-03-12 | 2015-07-28 | Imperial Innovations Limited | Anti-virus therapy for respiratory diseases |
WO2005087253A2 (en) * | 2004-03-12 | 2005-09-22 | University Of Southampton | Interferon-beta for anti-virus therapy for respiratory diseases |
US7569216B2 (en) | 2004-03-12 | 2009-08-04 | University Of Southampton | Anti-virus therapy for respiratory diseases |
US20070134763A1 (en) * | 2004-03-12 | 2007-06-14 | University Of Southampton Highfield | Anti-virus therapy for respiratory diseases |
EP3011953A1 (en) | 2008-10-29 | 2016-04-27 | Ablynx N.V. | Stabilised formulations of single domain antigen binding molecules |
EP4104821A1 (en) | 2008-10-29 | 2022-12-21 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
WO2014184352A1 (en) | 2013-05-17 | 2014-11-20 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof |
EP3511018A1 (en) | 2013-05-17 | 2019-07-17 | Ablynx NV | Stable formulations of immunoglobulin single variable domains and uses thereof |
WO2017147248A1 (en) | 2016-02-24 | 2017-08-31 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
Also Published As
Publication number | Publication date |
---|---|
KR100384353B1 (en) | 2003-10-04 |
CN1073119C (en) | 2001-10-17 |
EP0759939A4 (en) | 1998-05-27 |
EP0759939A1 (en) | 1997-03-05 |
CN1151168A (en) | 1997-06-04 |
US6231851B1 (en) | 2001-05-15 |
US6123936A (en) | 2000-09-26 |
AU2514295A (en) | 1995-12-05 |
KR970703366A (en) | 1997-07-03 |
NZ285664A (en) | 1998-07-28 |
MX9605717A (en) | 1998-05-31 |
DE69534318T2 (en) | 2006-04-20 |
CA2190502A1 (en) | 1995-11-23 |
ES2245780T3 (en) | 2006-01-16 |
DE69534318D1 (en) | 2005-08-25 |
EP0759939B1 (en) | 2005-07-20 |
WO1995031479A1 (en) | 1995-11-23 |
ATE299892T1 (en) | 2005-08-15 |
AU696387B2 (en) | 1998-09-10 |
US6479049B1 (en) | 2002-11-12 |
JPH10500672A (en) | 1998-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6479049B1 (en) | Methods and compositions for the dry powder formulation of interferons | |
EP0825885B1 (en) | Pulmonary delivery of aerosolized medicaments | |
US6509006B1 (en) | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments | |
US6673335B1 (en) | Compositions and methods for the pulmonary delivery of aerosolized medicaments | |
US20030035778A1 (en) | Methods and compositions for the dry powder formulation of interferon | |
NZ281112A (en) | Powdered insulin delivered as an aerosol | |
JPH05963A (en) | Polypeptide composition | |
AU740760B2 (en) | Pulmonary delivery of aerosolized medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NEKTAR THERAPEUTICS, CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:INHALE THERAPEUTIC SYSTEMS, INC.;REEL/FRAME:013525/0753 Effective date: 20030113 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NOVARTIS PHARMA AG, SWITZERLAND Free format text: ASSIGNMENT OF PATENT RIGHTS;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:022071/0001 Effective date: 20081231 Owner name: NOVARTIS PHARMA AG,SWITZERLAND Free format text: ASSIGNMENT OF PATENT RIGHTS;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:022071/0001 Effective date: 20081231 |